	G	•
	VOID S	HEET
Lice	ense fee hanagement	Branch, C. Fleming-
ROM:	ADAM	
UBJECT: VOI	DED APPLICATION	
	*	
	389917	
		Kansas City, MO
ate Voided:	8-1-90	
leason for Void:	Licensing	action
innearia	in alread	y authorized on
A .	IN I DA	0
licende.	Voided aft	en rement.
	and a state of the local state of the state of	
		L. L. alam 8-1-90
		Signature Jate
Attachment:	Come of	
Utficial Record Voided Action	Copy of	
FOR LEMB USE ONL	Y	
Final Review of	VUID Completed:	
	thorized and proces	ssed
	alter	- rev
No Refun	V	rec
L ree Exem	pt or Fee Not Requi	/
Comments:		Log completed
		Processea by:

190

t

44.68

0

9101090395 900801 REG3 LIC30 MATLSLICENSING PDR

MLAD

			:					USE			
BETWSEN:					INFO	RMAT	10N	FROM	LTS		
LICENSE	FEE MANAGEMENT BRANC	H, ARM		PROGR				0			
REGIONAL	AND LICENSING SECTIONS		1	STATUS FEE CL EXP. [FEE CL 11111	ATEGO DATE: DMMEN	RY: 199 TS:	3C 3 4093 3N_N	0 016	LON_	5/5/	/87_
LICENSE	FEE TRANSMITTAL										
A. REGI	ON										
APPL RECE DOCK CONT LICE	ROL NO.: 389 NSE NO.: 24~	726 11339									
2. FEE AMDU CHEC	ATTACHED \$370.00 NT: \$370.00 K NO.: 223233										
3. COMME	NTS										
		SIGNED DATE	 	Dette 27-9		447 447 447 34 447 447 447 34	, en an en an				/
8. LICEN	SE FEE MANAGEMENT BR	ANCH COHEC	A WHEN	MILES	TONE	,03	IS E	NTER	ED /	\sqrt{r}	
1. FEE	CATEGORY AND AMOUNT:		2.5	20	ET	(X	<u>C</u>	80° 80 50 101			
	DMENT	GATION MAY	DE PR	OC E S S E	D FO	R I					
з. отне	R		10. de 10. de 10. de 1								
	600 400 500 600 80 80 80 80 50 50 50 50 80 80 80 80 80 80 80 80	SIGNED DATE	184 305 305 186 386 386 486 4 - 486 386 386 386 386 3 - 866 386 386 386 386	- Gs	A.	90	an an an an an ar an	an an an an an			

ŧ



NRCTADM

July 22, 1990

William J. Adam, Ph.D. Material Licensing Section U. S. Nuclear Regulatory Commission Region III 799 Roosevelt Road Glen Ellyn, Illinois 60137

RE: Am adment Request for NRC Materials License Number 24-16617-01MD Kansas City, MO. This is an amendment request that we have been discussing with Dr. Bill Adam. I would appreciate it very much if he was assigned this amendment request. RECEIVED

Dear Dr. Adam:

Please amend our NRC Materials License Number 24-16617-03MD, Kansas City, for authorization to label white blood cells (WBCs) with Tc-99m Ceretec and to dispense this material upon prescription to authorized recipients. In support of this request please see the attached documents relative to the use of this NDA drug for a use not listed in the package insert.

This material will be administered to the patient using the same route of administration and in the same recommended quantities as stated in the package insert. The radiation dose to the critical organs is about the same for Tc-99m and In-111 since the amount of activity is larger using Tc99m. The images thus the diagnostic information is superior using Tc99m since better statistics are available for imaging.

I have asked Dr. Hoogland to include a letter to you concerning his conversation with the FDA contact. He has also listed the information contained in the attached documentation.

Your consideration in this matter is appreciated.

Sincerely, Werner

Frank M Comer Manager, Regulatory Compliance

cc. Deborah Kaminsky Or Hoogland License file

06

Log Remitter Check No. . Amount Fae Category Typa of Fee Date Chicek F& Date Completed

Enclosure: Amendment fer

JUL 26 1990

REGION III

8991

In potators in high-tech pharmacy services^{2,6} 1990

International Corporation • 20001 • Talex MCI 67-18642 Syncor CONTROL INJ. 🚟 Syncor International Corporation • 20001 Prairie Street • Chatsworth, California 91311



14166

VENDOR CODE	
PAY TO	EXPENSE MONTH
	DATE
	DUE DATE
	AMOUNT \$

CO. NO. SYN

1EQ. #	P.O. #	ACCOUNTING DISTRIBUTION					
OR		Account	Cost Center	Amount			
				3.10			
			angles, e a sur a part and an in a fuir strain (, a				
PECIALINSTRUCTION	IS						
Vin Aur	File X March 1			***			
	The second secon						
		Requested By					
		Approved By	and Millen	iai I			
Please Check One:	C.O.D.	ADVANCE PAT	YMENT				
	DOWN PAYMENT						
	[mmm]	Land NO NYCICL P	The O has I Y has be				
	OTHER						



July 20, 1990

William J. Adam, Ph.D. Material Licensing Section U.S. Regulatory Commission Region III 799 Roosevelt Road Glen Ellyn, Illinois 60137

Dear Dr. Adam:

With regard to Syncor Nuclear Pharmacies providing nuclear medicine departments Tc-99m Cereted (HMPAO) labeled White Blood Cells (WBCs), the following data are provided for your records:

- Letter: Syncor to FDA requesting definition that the Syncor method for preparing Tc-99m WBCs is considered the dispensing of an approved drug for an unapproved use, and therefore, does not require an IND status.
- Letter: FDA to Syncor confirming IND status is not required for the approved drug (Tc-99m Ceretec) being used to label WBCs for patient administration (unapproved use of an approved drug in physicians practice of medicine).
- ICRP Publication 53 Reference A. Radiation dosimetry In-111 WBCs
 - (Current commercial WBC labeling product)
 - B. Radiation Dosimetry Tc-99m WBCs (Proposed product)
- Package insert for Tc-99m Ceretec which indicates radiation dosimetry for any drug which may leach from WBCs which is minimal.
- Journal Article: Inflammation: Imaging with Tc-99m HMPAO-labeled leukocytes (Ceretec = HMPAO) which also contains data relating to radiation dosimetry and clinical efficacy.
- Journal Article: In Vitro and In Vivo Evaluation of Granulocyte Labeling with Tc-99m HMPAO which describes a labeling procedure, Tc-99m wash out values, biodistribution, and clinical efficacy.
- 7. Journal Article: Tc-99m Ceretec-Labeled Leukocytes in Detection of Inflammatory Lesions: Comparison with Ga-67 Citrate.

Innovators in high-tech pharmacy services

Syncor International Corporation * 20001 Prairie Street * P.O. Box 2185 * Chatsworth, California 91313-2185 (818) 886-7400 * FAX (818) 993-3507 * Telex MCI 67-18642 Syncor CHATS

89917

CONTINUE IN.

Mr. Mark Anderson of the FDA (301/443-5963) has verbally verified on July 13, 1990 that dispensing Tc-99m Ceretec WBCs instead of In-111 WBCs upon a physicians prescription for patient diagnostic studies is recognized as an unapproved clinical use of an approved radiopharmaceutical. This clinical application is outside the requirements of 21 CFR Parts 50 and 56, respectively. Neither IRB approval, nor patient consent is required when Tc-99m Ceretec WBCs are administered to a patients upon a physician prescription for the purpose of diagnosing their condition.

This diagnostic clinical application of Tc-99m Ceretec WBCs is identical to the use of Tc-99m DTPA as a lung aerosol, Tc-99m sulfur colloid for evaluating gastric emptying times, In-111 DTPA for evaluating gastric emptying times, Tc-99m MAA for radionuclide venography, Tc-99m and T1-201 for parathyroid evaluation, Tc-99m sulfur colloid or Tc-99m MAA for Levine shunt patency, Tc-99m red blood cells for radionuclide venography, etc. These clinical diagnostic procedures require neither IRB approval nor patient consent before accomplishing diagnostic studies not listed in the package insert of an NDA approved radiopharmaceutical.

Syncor requests that its FDA communications contained in this letter should be kept confidential.

If I can be of any additional service, please ask.


Sincerely,

All

Dennis R. Hoogland, Ph.D., BCNP Manager, Technical Training and Development

cc: Frank Comer, Syncor RSO

Enclosures



May 1, 1989

Mark D. Anderson Robert L. West, M.S. Consumer Safety Officers United States Food and Drug Administration Center Drugs and Biologics Office Drug Research and Review Radiopharmaceutical Drug Products 5600 Fishers Lane Rockville, Maryland 20857

Dear Messrs. Anderson and West:

Syncor nuclear pharmacy service centers have received physician requests to label white blood cells (WBCs) with technetium-99m Ceretec based on clinical literature. Technetium-99m Ceretec, which is approved as an adjunct in the detection of altered regional cerebral perfusion in stroke, will be administered to patients as Tc-99m labeled white blood cells to diagnose inflammatory processes.

Based on past responses from FDA, filling prescriptions for Tc-99m labeled WBCs using an approved radiopharmaceutical Tc-99m Ceretec for an "unapproved use" is within FDA's position relative to the use of approved drugs (21 CFR 312.2(b); April 1982 FDA Drug Bulletin).

Before approving the dispensing of Tc-99m labeled WBCs, Syncor would like a reply from your office that FDA's position has not changed relative to previous communications citing the above references.

Thank you in advance for your attention to our request.

Sincerely, RHU/

Dennis R. Hoogland, Ph.D. Manager, Technical Training and Development

Innovators in high-tech pharmacy services

Syncor International Corporation * 20001 Prairie Street * P.O. Box 2185 * Chatsworth, CA 91313-2185 (818) 886-7400 * FAX 886-6028 * Telex MCI 67-18642 Syncor CHATS

89917

CONTROL NU.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration Rockville MD 20857

MAY | 7 1989

Syncor International Corporation 20001 Prairie Street P.O. Box 2185 Chatsworth, California 91313-2185

Attention: Dennis R. Hoogland, Ph.D. Manager, Technical Training and Development

Dear Dr. Hoogland:

Reference is made to your May 1, 1989 letter regarding clarification of FDA's position stated in the April 1982 FDA Drug Bulletin and IND regulations concerning the use of approved drugs for unapproved indications. Specifically, you have inquired about the acceptability, under the practice of medicine and/or pharmacy, for a licensed nuclear pharmacy to radiolabel a patient's white blood cells (WBCs) with Ceretec, a radiopharmaceutical approved by FDA for the detection of altered regional perfusion in patients with stroke. Once labeled with Ceretec, the WBCs are to be used for an indication which is not approved, i.e., localization of inflammatory processes.

As you have mentioned, FDA published revised New Drug, Antibiotic, and Biologic Drug Product Regulations in the <u>Federal Register</u> (52 <u>FR</u> 8798-8847) on March 19, 1987, which became effective on June 19, 1987. These regulations [21 CFR 312.2 (b)(1)] state that the clinical investigation of a drug product that is lawfully marketed in the United States is exempt from the IND requirements if <u>all</u> of the following apply:

- The study does not involve a route of administration or dosage level or use in a patient population or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the product.
- The study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling or advertising for the drug;
- 3. Informed patient consent is to be obtained and the study has been reviewed and approved by an Institutional Review Board (IRB) in accordance with the requirements of 21 CFR Parts 50 and 56, respectively.

Page 2 Dr. Hooglund

4. The investigation is conducted in compliance with the requirements of 21 CFR 312.7, i.e., the investigational drug may not be represented as safe or effective for the purposes for which it is under investigation nor may it be commercially distributed, test marketed or sold.

In addition to FDA's receit actions, on April 1, 1987 the United States Nuclear Regulatory Commission (NRC) revised their regulations and published them as a final rule in the Federal Register of October 16, 1986 (51 FR 35932-36951). These regulations state that the NRC will no longer require a physician to obtain an IND in order to administer an approved radiopharmaceutical by a route or for an indication other than that provided for in the approved labeling for the product.

Like the NRC's regulation, FDA's new regulation is not intended necessarily to tie the investigator to the dose, route of administration and patient population(s) described in the drug product's approved labeling, but rather is designed to permit deviation from the approved labeling to the extent that such changes are supported by the scientific literature and generally known clinical experiences. As noted in the April 1982 FDA Drug Bulletin, FDA does not regulate the practice of pharmacy or medicine, which the Agency has consistently viewed as including the use of marketed drugs for unlabeled indications in the "day to day" treatment of patients.

Upon review of the information provided in your May 1, 1989 communication, we conclude that your proposal to label WBCs with Ceretec meets the requisites of 21 CFR 312.2(b)(1) and may be performed under the practice of medicine and/or pharmacy without benefit of an IND. However, as noted in the regulation cited above and if clinical studies are to be conducted, both patient informed consent and internal review and approval by the appropriate committee within the referring institution are required. In addition, no data have been submitted to the Agency to support the safety and effectiveness of using WBCs labeled with Ceretec for localization of imflammatory processes. Therefore, you may not actively promote the use of Ceretec for the unlabeled indication.

Sincerely yours

A. Eric Jones, M.D. Group Leader Division of Radiopharmaceutical, Surgical and Dental Drug Products Office of Drug Research and Review Center for Drug Evaluation and Research

CONTROL NO. .. 89917

Code N.159Z

Ceretec'' kit for the preparation of Technetium Tc99m Exametazime Injection

Diagnostic radiopharmaceutical-For intravenous single use only


DESCRIPTION

The Amersham Ceretec[™] kit is supplied as packs of 5 single dose vial units for use in the Preparation of a technetium Tc99m exametazime infravenous injection as a diagnostic radiopharmaceutical for use as an adjunct in the detection of altered regional cerebral pertusion. Each single dose vial unit contains a pre-dispensed sterile, nonpytogenic, twophilized mixture of 0.5 mg exametazime [(RR,SS)+4.8-diaza-3.6.6.9-tetramethylundecane-2, 10-dione bisoxime], 7.6 µg stannous chloride dinydrate (minimum stannous tin 0.6 µg, maximum total stannous and stannic tin 4.0 µg per visi) and 4.5 mg sodium chloride, sealed under nitrogen atmosphere with a rubber closure. The product contains no antimicrobial preservative.

Caution: Federal (U.S.A.) Law prohibits dispensing without a prescription.

Prior to Lublication of the USAN, exametazime was formerly known as hexamethylpropylene amine oxime (HM-PAO). The name HM-PAO appears in many publications.

The structural formula of exametazime is



GINHIN, O

When sterics syrogen-free sodium pertechnetate Tc99m in isotonic saline is added to the vial, a Tc99m complex of exametazime is formed

Administration is by intravenous injection for diagnostic use.

Physical Characteristics

Technetium Tc99m decays by isomeric transition with a physical half-life of 5.03 hours.⁽¹⁾ Photons that are useful for imaging studies are listed in Table 1.

Table 1. Principal radiation emission data-technetium Tc99m

Radiation	Mean %/ disintegration	Mean energy (keV)
Gamma 2	87.87	140.5

 Dillman, L.T. and Von der Lage, F.C. Radionuclide Jacay schemes and nuclear parameters for use in radiation-dose estimation. MIRD Famphiet No. 10, p62, 1975.

External radiation

The specific gamma ray constant for technetium Tc99m is 206 microCoulomb kg 1/37 MBq-h. (0.8 R/millicure-h) at 1 cm. The first hall-value thickness of lead (Pb) for technetium Tc99m is 0.2 mm. A range of values for the relative attenuation of the radiation emitted by this radionucide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the external radiation exposure by a factor of 1.000.

Table 2. Radiation attenuation by lead shielding

Shield thickness	Goefficient of
(Pb) mm	attenuation
0.2	0.5
0.95	10-1
1.8	10-2
2.7	10-3
3.6	10-4
4.5	10-5

To correct for physical decay of this radionuclide, the fractions that remain at selected intervals relative to the time of calibration are shown in Table 3.

Table 3. Physical decay chart + Tobim nall life 6.03 hours

Hours	Fraction remaining	Hours	Fraction temaining
01	1,000	7	0 447
1.	0.891	8	0.399
2	0.795	9	0.355
3	0.708	10	0.317
4	0.631	11	0.282
5	0.563	12	0.252
6	0.502	24	0.063

*Calibration time (time of preparation)

CLINICAL PHARMACOLOGY

When technetium Tc99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc99m complex is formed. This lipophilic complex is the active molety. It converts with time to a secondary complex which is less lipophilic. When the secondary complex is isolated from the lipophilic species, it has been shown to be unable to cross the blood-brain-barrier. A consequence of the conversion of lipophilic to secondary complex is that the useful life of the reconstituted agent is restricted to 30 minutes.

Studies in normal volunteers have shown that the technetium To99m complex of the RR.SS(d.I)

diastereoisomer of examétazime is rapidly cleared from the blood after intravenous injection. Uptake in the brain reaches a maximum of 2.5-7.0% of the injected dose within one minute of injection. Up to 15% of the activity is eliminated from the brain by 2 minutes post injection, after which little activity is lost for the following 24 hours except by physical decay of technetium TG99m. The activity not associated with the brain is widely distributed throughout the body particularly in muscle and soft fissue. About 30% of the injected dose is found in the gastrointestinal tract immediately after injection and about 50% of this is excreted through the intestinal tract over 46 hours. About 40% of the injected dose is excreted through the kidneys and urine over the 48 hours after injection resulting in a reduction in general muscle and soft tissue background.

INDICAT: ONS AND USAGE

Technetiu Tc99m exametazime scintigraphy may be use "5.2 "funct in the detection of altered regional c9 per usion in stroke.

CONTESTICATIONS

* ne kňown

PRECAUTIONS

The contents of the Ceretec vial are not radioactive. However, after the sodium pertechnetate Tc99m is added, adequate shielding of the final preparation must be maintained.

The contents of the Ceretec[™] vial are intended only for use in preparation of technietium Tc99m exametazime injection and are NOT to be administered directly to the patient.

A thorough knowledge of the normal distribution of intravenously administered technetium 7c99m exametazime injection is essential in order to interpret pathologic studies accurately.

The technetium Tc99m labeling reaction involved in preparing technetium Tc99m exametazime injection depends on maintaining bin in the divalent (reduced) state. Any oxidant present in the sodium pertechnetate Tc99m employed may adversely affect the quality of the preparation. Sodium pertechnetate Tc99m containing oxidants should not be used for the preparation of the labeled product. To meet the last requirement, a generator must be eluted within 24 hours prior to obtaining any eluate for reconstitution with the Ceretec kit.

Sodium Chioride Injection, USP must be used as the diluent. Do not use bacteriostatic sodium chioride as a diluent for sodium perfectinetate Tc99m injection because it will increase the oxidation products and adversely affect the biological distribution of Ceretec.

GENERAL

The contents of the Ceretec vial are sterile and pyrogen tree. The vial contains no bacteriostatic preservative. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation of the radiopharmaceutical.

Technetium To99m exametazime injection, like other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnet. Care should also be taken to minimize radiation exposure to the patient consistent with proper patient interagement. Radiobinarimaceuticials encode be used only by or under the control of physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

To minimize radiation dose to the biadder, the patient should be encouraged to void when the examination is completed and as often thereafter as possible. Adequate hydration should be encouraged to permit frequent voiding.

Carcinogenesis, Mutagenesis, Impairment of Fertility No long term animal studies have been performed to evaluate carcinogenic potential or whether technetium To99m exametazime affects fertility in males or females. Studies in rats did not demonstrate mutagenic notential following intraperitoneal administration at doses of 70, 140 and 280 mg/kg.

Pregnancy Category C

Since adequate reproduction studies with technetium Tc99m exametazime have not been performed in animals to determine whether this drug affects fertility in males and females, has teratogenic potential, or has other adverse effects on the fetus, this radiopharmaceutical preparation should not be administered to pregnant or hursing women unless it is considered that the benefits to be gained outweigh the potential hazards.

Ideally, examinations using radiopharmaceuticals, especially those which are elective in nature, in women of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.

Nursing Mothers

Technetium Tc99m is excreted in human milk during lactation. It is not known whether exametazime is excreted in human milk. Therefore, formula feedings should be substituted for breast feeding.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Rash with generalized erythema, facial edema and fever has been reported. A transient increase in blood pressure was seen in 8% of patients.

DOSAGE AND ADMINISTRATION

The user should wear waterproof gloves and use shielding at all times when handling the vial and syringes.

The recommended dose range for i.v. administration, after reconstitution with sodium perfectinetate Tc99m. to be used in the average adult (70 kg) is 370-740 MBg (10-20 mGi).

Do not use the final radiopharmaceutical preparation after 30 minutes from the time of reconstitution. Discard any unused material.

Dynamic imaging may be performed between 0 to 10 minutes following injection. Static imaging may be performed from 15 minutes up to 6 hours after injection.

Although gross abnormalities of regional cerebral perfusion may be visualized by planar imaging, it is strongly recommended that SPECT imaging is carried out to maximize the value of the study.

RADIATION DOSIMETRY

Based on human data, the absorbed radiation dose to an average human adult (70 kg) from an intravenous injection of this product are estimated below. The values are listed as µGy/MBq [rads/mCi] with unination every 2 hours. Bladder wall dose is 19 µGy/MBq [0.07 rads/mCi] with 4 hour unination and 89 µGy/MBq [0.33 rads/mCi] with no unination.

Table 4. Estimated Absorbed Radiation Dose*

arget organ	Absorbed µGy/MBg		T099m exameta mGy/740 MBg	
achrymai clamts	69.4	0.258	51.36	5.16
lalbudder wall	51.0	0.19	37.74	3.80
Cidmery	35.0	0.13	25.90	2.60
hyroid	210	0.10	19.95	2.00
coer area intestine wa	21.0	0.079	15.54	1.58
NB1	15.0	0.054	11.10	1.08
imal mestne wall	12.0	0.044	8.88	0.68
ower lanse intestine wa		0.054	11.10	1.08
innary bladder wal	13.0	0.047	9.62	0.94
itain.	6.9	0.026	5.11	0.52
Warres	8.3	0.023	4.66	0.46
esses -	18	0.007	1.33	0.14
Nhoie body	3.6	0.013	2.66	0.26
ked Marrow	3.4	0.013	2.52	0.26
sone Surfaces	4.8	0.018	3.55	0.36
yes	69	0.026	\$11	0.52

CONTROL NU. 89991 Port Promision Center

NIMAL TOXICOLOGY SUMMARY Solid toxicity slucies have been performed on intravenously administered Ceretec in male and female ats and rabbits. No adverse reactions or mortality were observed at a dose equivalent to the single intertion of 200 times the maximum human equivalent dose outreen day repeat-dose studies in rats and rabbits at a sumulative dose of up to 14,000 times the maximum uman equivalent dose did not reveal adverse reactions. Suphamilities, or mortality At termination thorough isobathology hematology and blood chemistry revealed to abnormalities.

HOW SUPPLIED

γ.

The kit comprises five individual vials of sterile, nonovrogenic, treeze-dried mixture of examplazine route hioride dihydrate and sodium chloride, ten radiation abels, five sterile alcohol swabs, five (adiochemical purity worksheets, and one package inset). The vial and ontents are sealed under a nitrogen atmosphere with a ubber stopper

PROCEDURE

For the Preparation of Technetium Tc99m Exametazime injection

Use aseptic technique throughout.

- Place one of the viais in a suitable shielding container and swab the rubber septum with the sterile swab provided.
- 2) Using a 10 mi syringe inject into the shielded vial 5 ml of sterile eluate from a technetium Tc99m generator (see notes 1-4). Before withdrawing the syringe from the vial withdraw 5 ml of gas from the space above the solution to normalize the pressure in the vial. Shake the shielded vial for 10 seconds to ensure complete discourse of the proving. dissolution of the powder.
- Assay the total activity and calculate the volume to be injected. The patient dose should be measured in a suitable radioactivity calibration system immediately. prior to administration.
- Complete the label provided and attach to the vial shield. The technetium Tc99m exametazime injection is ready for quality control.
- 5) Maintain adequate shielding of the radioactive preparation
- Do not use the preparation after 30 minutes from time of formulation. Discard any unused material.
- Visually inspect the reconstituted material at a safe distance behind leaded glass, and do not use if there is evidence of foreign matter.

- Cautionary Notes 1) 0.37-1 11 GBg (10-30 mCi) technetium Tc99m may be added to the vial.
- 2) Before reconstitution the generator eluate may be adjusted to the correct radioactive concentration (0.37-1.1) GBq [10-30 mCi] in 5 ml) by dilution with preservative-free saline for injection.
- 3) Generator eluate more than 2 hours old should not be used. For the highest radiochemical purity reconstitute with freshly eluted technetium Tc99m generator eluate.

4) Use only eluate from a technetium Tc99m generator which was previously eluted within 24 hours.

5) The pH of the prepared injaction is in the range 9.0-9.8.

Quality Control

Quality Control Radiochemical purity determination must be performed before administration to the patient. Three potential radiochemical impurities may be present in the prepared injection of the lipophilic complex technetium Tc99m exametazime. These are a secondary technetium Tc99m exametazime complex, free perfectinetate and reduced-hydrolyzed-technetium Tc99m. A combination of 3 chromatographic systems is necessary for the complete definition of the radiochemical composition of the injection. nection

The following protocol has been designed to enable analysis of the radiochemical purity of Geretec (99mTc-exametazime) to be performed within 2 minutes of reconstitution taking approximately 15 minutes.

Equipment and Eluents

Seiman ITLC/SG strips 6 cm x 0.7 cm (available from Atomic Products – Black Strip) Whatman strips 6 cm x 0.7 cm (available from Atomic Products – Red Strip)

- Products Red Strip) MEK (methyl ethyl ketone (butanone)) (Aldridge Cat #27069-5-99.9 + % HPLC Grade) 2.9% aqueous sodium chicroide (without bacteriostat) 50% aqueous acetonitrile (Aldridge Cat #27071-7 99.9 + % HPLC Grade) Dilute with water for injection without bacteriostat <u>biass</u> test tubes (12 x75 mm) mi syringes with 25 gauge needles suitable counting equipment

- suitable counting equipment

Method

- Prepare three chromatopraphy tubes containing 0.9% sodium chioride, 0.2-0.3 ml of tresh MEK and 50% acetonitrile respectively. Identity the solvent in each tube.
- 2) Prepare two ITLC/SG (black) strips and one paper (red) strip. Each are marked by the manufacture 1.0 cm from the bottom as the point of origin
- 3) Reconstitute a Ceretec vial according to the package
- 4) Apply 5 µl samples of Ceretec to the origin of the three Apply 5 at samples of central to the origin to the trees strips within 15 minutes of reconstitution. Immediately place one (TLC/SG (black) strip into the same tube, the second (TLC/SG (black) strip into the MEK tube and the paper (red) strip into the 50% aceton(trile tube) Make sure strips are not adhering to the side of the test tube
- 5) The ITLC/SG MEK (black) strip takes approximately 45 seconds to run. When the eluate has reached the solvent front remove the strip from the tube with forceps and immediately cut 1.0 cm above the origin.
- 6) The ITLC'SG saline (black) strip takes approximately 45 seconds to run. When the eluale has reached the solvent front remove the strip from the tube with torceps and immediately cut 2.5 cm above the origin.
- 7) The Whatman paper CH₃CN (red) strip takes approximately 100 seconds to run. When the eluate has reached the solvent from remove the strip from the tube with forceps and immediately cut 0.5 cm above the origin.
- 8) Count the separate sections of each strip to determine. the activity distribution. Make sure proper counting geometry is maintained attempting to reduce any interterence from equipment dead time.
- 9) Determine
- Determine % top of saline strip (= % pertechnetate) % bottom of saline strip % bottom of MEK strip (= % lipophilic exan...me.complex) (= % lipophilic exan. me.complex) % bottom of Whatman paper strip (= % reduced-hydrolyzed-Tc)
- A radiochemical purity of >80% may be expected
- provided the measurement has been carried out within 30 minutes of reconstitution.

interpretation of Chromatograms

System 1 (ITLC: MEK (butanone)) Secondary Tc exametazime complex and reduced-hydrolyzed-Tc remain at the origin.

Lipophilic Tc exametazime complex and pertechnetate migrate at R, 0.8-1.0.

System 2 (ITLC: 0.9% sodium chloride) Lipophilic Tc exametazime complex, secondary Tc exametazime complex and reduced-hydrolyzed-To remain at the origin.

Pertechnetate migrates at R. 0.8-1.0

System 3 (Whatman No. 1: 50% aqueous acetonitrile) Reduced-hydrolyzed-Tc remains at the origin.

Lipophilic To exametazime complex, secondary To exametazime complex and pertechnel, te migrate at R. 0.8-1.0

Storage

Store the kit at 2-25 °C.

Store the formulated drug at room temperature (15-25 °C) using appropriate radiation shielding

The Illinois Department of Nuclear Safety has approved this reagent kit for distribution to persons licensed to use by-product material identified in § 35,200 of 10 CFR Part 35 and to persons who hold

an equivalent license issued by an Agreement State

Manufactured by: Amersham International pic Amersham England



2636 S. Clearbrook Dr., Anington Heights, IL 60005 1-312-593-6300 pr. 1-800-323-0668 (Toll Free)

277019A Printed in U.S.A. 12/88 Amersham and Ceretec are trademarks of Amersham International plc

RADIATION PROTECTION

ICRP PUBLICATION 53

Radiation Dose to Patients from Radiopharmaceuticals

A report of a Task Group of Committee 2 of the International Commission on Radiological Protection

ADOT' ED BY THE COMMISSION IN MARCH 1987

PUBLISHED FOR

The International Commission on Radiological Protection

bis



PERGAMON PRESS

OXFORD · NEW YORK · BEIJING · FRANKFURT SÃO PAULO · SYDNEY · TOKYO · TORONTO

CATCRP 18:1-4-4

U.K.	Pergamon Press plc. Headington Hill Hall. Oxford OX3 0BW, England
U.S.A.	Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, New York 10523, USA
CANADA	Pergamon Press Canada, Suite No 271, 253 College Street, Toronto, Ontario M2J 1P9, Canada
AUSTRALIA	Pergamon (Aust.) Pty. Ltd., PO Box 544. Potts Point, NSW 2011, Australia
PEDERAL REPUBLIC OF GERMANY	Pergamon Press GmbH, Hammerweg 6, D+6242 Kronberg-Taunus, Federal Republic of Germany
JAPAN	Pergamon Press Ltd. 8th Floor, Matsuoka Central Building, 1-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160, Japan
BRAZIL	Pergamon Editora Ltda. Rua Eça de Queiros, 346 CEP 04011, São Paulo, Brazil
PEOPLE'S REPUBLIC OF CHINA	Pergamon Press, Qianmen Hotel, Beijing. People's Republic of China
	Copyright @1988 The International Commission on Rediological Protection
	da an

The International 4 semission on Radiological Protection encourages the publication of translations — Six report. Permission for such translations and their publication will normally be given free of charge. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise or republished in any form, without permission in writing from the copyright

First edition 1988 ISBN 0-08-035591-9 ISSN 0146-6453

CONTRACTOR CONTRACTOR OF AN ADDRESS OF A DESCRIPTION OF A DESCRIPANTA DESCRIPTION OF A DESCRIPTION OF A DESC

1

Typeset by Catswold Typesetting Ltd., Gloucester Printed in Great Britain by A. Wheaton & Co. Ltd., Exeter Preface Quantitie 1. GENI 1. Intr 2. Sele 3. Sele 4. Bios 5. Met 5.1. 5.2. 5.3. 6. Effe 6.1.

6:

7. Imr 7 1 7 2 Referen

Arren

A 1 A 1

×.

8.5

5

1.1.1

11.9

RADIATION DOSE TO PATIENTS FROM RADIOPHARMACEUTICALS

43 WBC

Te

TECHNETIUM-LABELLED WHITE BLOOD CELLS (LEUKOCYTES) Somte

Biokinetic Model

The same model is used as for indium-labelled leukocytes (see p. 255), with the exception that, in view of the short physical half-life, the retention half-times are set to infinity.

References

金水の時

いまんなあ

「「「「「「「」」」

からのの

Hanna, R., Braun, T., Levendel, A. and Lomas, F. (1984). Radiochemistry and biostability of autologous leukocytes labelled with ^{99m}Tc-stannous colloid in whole blood. Eur. J. Nucl. Med. 9, 216-219.
 Kelbaek, H., Fogh, J., Gjorup, T., Bülow, K. and Vestergaard, B. (1985). Scintigraphic demonstration of subcutaneous abscesses with ^{99m}Tc-labeled leukocytes. Eur. J. Nucl. Med. 10, 302-303.

Schroth, H. J., Oberhausen, E. and Berberich, R. (1981). Cell labelling with colloidal substances in whole blood. Eur. J. Nucl. Med. 6, 469-472.

Biokinetic Data

Organ (S)	E ₈	Т	a	$\tilde{A}_{\rm S}/A_{\rm 0}$
Blood	1.0	0 7 hr	0.60	1.87 hr
Liver	0.20	0 7 hr	-0.60 -0.40	1.36 hr
Red marrow	0.30	0 7 hr	$ \begin{array}{r} 1.0 \\ -0.60 \\ -0.40 \end{array} $	2.05 hr
Spicen	0.25	0 7 hr	1.0 + 0.60 0.40	1.70 hr
Remaining tissues	0.25	0 7 hr	1.0 0.60 0.40	1.70 hr
		00	1.0	

BIOKINETIC MODELS AND DATA

Te 43 WBC

Te-LABELLED WHITE BLOOD CELLS (LEUKOCYTES)

m pi M

0. re al

11

IC M

6.02 hours

99m_{Tc}

	Organ	per u	Abso nit activity	orbed dose / edminist	ered (mGy/	MBq)
		Adult	15 year	10 year	5 year	1 year
	Adrenals Bladder vall Bone surfaces Breast GI-tract	8.9E-03 2.6E-03 1.3E-02 3.1E-03	1.2E-02 3.7E-03 1.7E-02 3.1E-03	1.8E-02 5.6E-03 2.8E-02 5.1E-03	2.5E-02 8.0E-03 5.0E-02 7.8E-03	4.28-02 1.48-02 1.08-01 1.38-02
	Stomach vell Small intest ULI vall LLI vell Heart	B.0E-03 4.9E-03 4.9E-03 3.9E-03 9.0E-03	9.6E-03 5.8E-03 6.0E-03 5.0E-03 1.1E-02	1.4E=02 8.8E=03 9.3E=03 7.6E=03 1.6E=02	2.0E-02 1.3E-02 1.4E-02 1.0E-02 2.3E-02	3.1E=02 2.2E=02 2.3E=02 1.8E=02 3.9E=02
* * *	Kidneys Liver Lungs Ovaries Pancreas	9.9E-03 2.0E-02 6.9E-03 4.2E-03 1.4E-02	1.2E-02 2.4E-02 9.0E-03 5.2E-03 1.6E-02	1.8E-02 3.6E-02 1.3E-02 7.5E-03 2.4E-02	2.5E-02 5.2E-02 2.0E-02 1.1E-02 3.3E-02	4.0E=02 9.2E=02 3.6E=02 1.8E=02 5.2E=02
•	Red marrow Spleen Testes Thyroid Uterus	2.2E-02 1.5E-01 1.7E-03 2.4E-03 3.8E-03	2.9E-02 2.1E-01 2.3E-03 3.7E-03 4.5E-03	4.5E-02 3.2E+01 3.4E-03 5.7E-03 6.8E-03	7.8E-02 4.8E-01 5.2E-03 9.1E-03 9.9E-03	1.5E=01 B.7E=01 9.7E=03 1.7E=02 1.7E=02
	Other tissue	3.4E-03	4.28=03	6.08-03	9.08-03	1.6E-02
	Effective dose equivalent (mEsv/MBq)	1.7E-02	2.3E-02	3.58-02	5.48-02	9.88-02

232

RADIATION DOSE TO PATIENTS FROM RADIOPHARMACEUTICALS

49 WBC

INDIUM-LABELLED WHITE BLOOD CELLS (LEUKOCYTES)

Biokinetic Model

The fate of intravenously administered leukocytes depends to a great extent on details in the preliminary isolation and *in vitro* labelling of the cells. The cells may become activated and damaged to a varying degree, resulting in an immediate uptake predominantly in the lungs and liver. When modern, more innocuous methods are used, there is only a very short transient holdup in the lungs, and the initial uptake in organs is effected by equilibration with the pools of marginating leukocytes. Cells initially remaining in the circulation show a blood clearance which is exponential with a half-life between 5 and 10 hr. There is a very slow excretion of label in the urine.

For absorbed dose calculations a model is proposed, where 60% of the cells are immediately distributed in liver, spleen, bone marrow and other tissues, and 40% circulate in the blood with a half-time of 7 hr, after which they are taken up in the same organs and tissues and in the same proportions as for the early uptake. The total uptake is taken to be 20% in the liver, 25% in the spleen, 30% in red bone marrow and 25% in other tissues. From all sites the activity is assumed to be eliminated with a half-time of 70 d, in analogy with the model proposed for ionic indium.

The model chiefly refers to granulocytes, which normally form the majority of cells in a preparation of mixed leukocytes. It may be inappropriate for other types of white blood cells, such as lymphocytes, having somewhat different biokinetics.

\$

The actual white blood cell suspension used for labelling may also contain erythrocytes and thrombocytes, which become labelled at the same time, and there may also be some unbound activity. The dose contributions from these other fractions of activity thus have to be added appropriately.

The ¹¹¹In-preparation may be contaminated with ^{114m}In and its daughter ¹¹⁴In. The effective dose equivalent per unit activity of these radionuclides is therefore presented in the dosimetric table.

References

Goodwin, D. A., Finston, R. A. and Smith, S. I. (1981). The distribution and dosimetry of In-111 labeled leucocytes and platelets in humans. In: Proc. Third Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, 1980 (FDA 81-8166), pp. 88-101. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Mountford, P. J., Allsopp, M. J., Hall, F. M., Wells, C. P. and Coakley, A. J. (1985). Leucocyte and contaminant cell-bound activities resulting from the labelling of leucocytes with ¹¹¹In-oxine. Eur. J. Nucl. Med. 10, 304-307.

Saverymuttu, S. H., Peters, A. M., Keshavarzian, A., Reavy, H. J. and Lavender, J. P. (1985). The kinetics of ¹¹³ Indium distribution following injection of ¹¹⁴ Indium labelled autologous granulocytes in man. Br. J. Haematol. 61, 675-685.
 Thakur, M. L., Seifert, C. L., Madsen, M. T., McKenney, S. M., Desai, A. G. and Park, C. H. (1984). Neutrophil labeling: Problems and pitfalls. Semin. Nucl. Med. 14, 107-117.

Weiblen, B. J., Forstrom, L. and McCullough, J. (1979). Studies of the kinetics of indium-111-labeled granulocytes. J. Lab. Clin. Med. 94, 246-255.

BIOKINETIC MODELS AND DATA

Biokinetic Data

WBC

ln.

49

Section .

E ₈	Т	a	\tilde{A}_{3}/A_{0}
1.0	0 7 hr	0.60	3.66 hr
0.20	0 7 hr	-0.60 - 0.40	18.1 hr
0.30	70 d 0 7 hr	1.0 - 0.60 - 0.40	27.2 hr
0.25	70 d 0 7 hr	1.0 0.60 0.40	22.7 hr
0.25	70 d 0 7 hr	1.0 0.60 0.40	22.7 hr
	1.0 0.20 0.30 0.25	1.0 0 7 hr 0.20 0 7 hr 70 d 0.30 0 7 hr 70 d 0.25 0 7 hr 70 d 0.25 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

In-LABELLED WHITE BLOOD CELLS (LEUKOCYTES)

111_{In} 2.83 days

> Absorbed dose per unit activity administered (mGy/Mhq)

	Organ								
		/ LubA	15 year	10 year	5 year	1 year			
*	Adrenals Bladder vall Bone surfaces Breas! GI-trac!	3 - 1E - 01 7 - 2E - 02 3 - 5E - 01 9 - 0E - 02	4.0E=01 1.0E=01 5.0E=01 9.0E=02	5.9E=01 1.6E=01 8.0E=01 1.5E=01	B:2E-01 2:4E-01 1:4E+00 2:3E-01	1.4E+00 4.1E-01 2.9E+00 3.9E+01			
	Stomach vall Small intest ULI vall LLI vall Heart	2.88.01 1.6E-01 1.6E-01 1.3E-01 1.7E-01	3.3E-01 1.9E-01 1.9E-01 1.6E-01 2.1E-03	4.98-01 2.98-01 3.08-01 2.48-01 3.06-01	6:8E=01 4:3E=01 4:7E=01 3:3E=01 4:3E=01	1.1E+00 7.1E=01 7.8E=01 5.4E=01 7.3E=01			
* *	Kidneys Liver Lungs Ovaries Pancreas	3.3E-01 7.1E-01 1.6E-01 1.2E-01 5.2E-01	3.9E=01 8.8E=01 2.1E=01 1.7E=01 6.1E=01	6.0E=01 1.3E+00 3.1E=01 2.4E=01 9.1E=01	8.7E-01 1.8F+00 4.6E-01 3.5E+01 1.3E+00	1.4E+00 3.2E+00 8.1E-01 5.6E-01 2.1E+00			
	Red marrov Spleen Testes Thyroid Uterus	6,9E-01 5,5E+00 4,5E-02 6,1E-02 1,2E-01	B.8E-01 7.6E+00 6.4E-02 9.0E-02 1.4E-01	1.3E+00 1.1E+01 9.9E-02 1.3E-01 2.1E-01	2.3E+00 1.7E+01 1.5E+01 2.1E+01 3.0E+01	4.5E.00 3.0E.01 2.8E-01 3.8E.01 5.0E-01			
	Other tissue	1.1E-01	1.48-01	2.0E=01	3.0E-01	5.3E-01			
	Effective dose equivalent (mSv/MBq)	5.98-01	7,9E×01	1.2E+00	1.8E+00	3.28+00			

Impurities: Effective dose equivalent (mSv/MBq of the imputity)

114min (49.51 d) 6.9E+01 9.3E+01 1.5E+02 2.5E+02 4.9E+02

256

The been : distri. blood durin ofion long t It is is evehalf-ti spleer half-t

> radio Inte and Urb. Williar

Br. .

Thaku

Mary E. Roddie, MRCP + A. Michael Peters, MD + Heather J. Danpure, PhD · Safiye Osman, MSc · Belinda L. Henderson, DNM · J. Peter Lavender, FRCR Michael J. Carroll, PhD • Rudi D. Neirinckx, PhD • J. Duncan Kelly, PhD

Inflammation: Imaging with Tc-99m HMPAO-labeled Leukocytes1

Leukocytes labeled with technetium-99m hexamethylpropyleneamine oxime (HMPAO) were used in 100 patients: 32 with suspected inflammatory bowel disease, 17 with fever of unknown origin, 21 with suspected abdominal sepsis, 20 with suspected bone sepsis, seven with bronchiectasis, and three with recent myocardial infarction. The' distribution of activity in patients subsequently shown not to have inflammatory bowel disease was similar to that previously described for indium-111-labeled leukocytes. However, in this study, activity was also seen in the kidneys and bladder and occasionally the gallbladder on both early (1-3 hours) and late (24 hours) views, and in the colon in late views. Migration of Tc-99m-labeled granulocytes was seen in inflammatory disease as early as 30 minutes after injection, while normal bowel activity was not seen before 4 hours. The sensitivity of Tc-99m-labeled leukocytes in the desection of inflammation was 100%, the specificity was 95%.

Index terms: Hexamethylpropyleneamine oxime + Inflammation, radionuclide studies. 70.125 + Leukocytes + Radionuclide imaging. radiation dose, 70.125 + Technetium, radioactive

Radiology 1988; 166:767-772

PRSNA, 1988

THE use of indium-111-labeled leukocytes has become established as a noninvasive and accurate means of diagnosing a variety of inflammatory conditions in which granulocyte migration is a prominent pathologic feature (1-4). For reasons of convenience, radiation dosimetry, expense, and image resolution, there have been many attempts to replace In-111 with technetium-99m in the form of lipid-soluble complexessuch as Tc-99m oxine (5), and with reducing agents such as Tc-99m stannous pyrophosphate (6, 7), Tc-99m porphyrin complexes (8), and Tc-99m tin colloid for phagocytic labeling (9, 10). None of these approaches has had lasting success, either because the complexes and/or labeling have proved unstable or, in the case of phagocytic labeling, because the cells have become activated and sequestered in the lungs immediately following injection (11).

A new agent, Tc-99m hexamethylpropyleneamine oxime (HMPAO), has recently been introduced for brain imaging (Amersham, Arlington Heights, Ill.) (12). Because it is lipophilic, it was thought that this agent could bind to blood cells; we have shown that it does label leukocytes and is nore stable with granulocytes than with mononuclear cells (13). We used Tc-99m HMPAO as a leukocyielabeling agent in a series of 100 patients suspected of having various inflammatory conditions.

PATIENTS AND METHODS

The 100 patients comprised six clinical groups. Thirty two had known or suspected inflammatory bowel disease, 17 had fever of unknown origin, 21 had suspected intraabdominal sepsis, 20 had suspected osteomyelitis, seven had bronchiectasis, and three had had a recent large myocardial infarction (Table 1). The clinical diagnosis was confirmed with surgery in 18 patients, with histologic and/or microbiologic findings in 46, and by means

of computed tomography (CT) in 17. The diagnosis was based on clinical findings in 13 patients. In three patients, no final · diagnosis was made, and in the three patients with myocardial infarction, no final diagnosis was made since no alternate techniques were available to confirm granulocyte migration into the myocardium.

First, 102 mL of fresh venous blood was collected into 18 mL of acid citrate dextrose (ACD, National Institutes of Health formula A). Then, 20 mL was immediately centrifuged at 2,000 g for 10 minutes to" give plasma, which was used to suspend cells for labeling and reinjection. The remaining 100 mL of anticoagulated blood was used to isolate mixed leukocytes, as previously described (3). A 6% wt/vol solution of hydroxyethyl starch was added to the whole blood in a ratio of one volume hydroxyethyl starch to ten volumes blood to promote red blood cell sedimentation.

Tc-99m HMPAO was formed by adding 450-600 MBq Tc-99m in 5 or 6 mL isotonic saline to a vial of Ceretec (Amersham) containing 0.5 mg HMPAO, 7.6 µg stannous chloride dihydrate, and 4.5 mg sodium chloride with nitrogen. After the vial was shaken to dissolve the contents, 4 or 5 mL of the Tc-99m complex was immedistely added to the mixed leukocytes. Aliquots of the remaining 1 mL were used to determine the extent of complex formation.

With method A, used in 18 patients, 5 mL Tc-99m complex was added to the mixed leukocytes, which were suspended in 5 mL phosphate-buffered saline enriched with 1 mL autologous plasma; that is, the cells were labeled in 10% plasma at an HMPAO concentration of 42 µg/mL.

With method B, used in 82 patients, 4 mL Tc-99m complex was added to mixed leukocytes in 1 mL plasma; that is, the cells were labeled in 20% plasma at an HMPAO concentration of 80 µg/mL.

With both methods, the cells were incubated for 10 minutes at room temperature, washed with 10-15 mL plasma containing hydroxyethyl starch, and centrifuged at 150 g for 5 minutes. The cell pellet was resuspended in 8-10 mL plasma without hydroxyethyl starch and reinected. The dose was about 200 MBg (5.5 mCi).

I From the Department of Diagnostic Radiology (M.E.R., A.M.P., B.L.H., J.P.L.), and the MRC Cyclotron Unit (H.J.D., S.O.), Hammersmith Hospital, Du Cane Rd., London, England, W12 OHS, and Amersham International, Bucks, England (M.).C., J.D.K., R.D.N.). Received May 27, 1987; revision requested July 13; revision received September 23; accepted October 1. Address reprint requests to A.M.P.



Is. Figures 1, 2. (1) Normal distribution of activity 3 hours after injection of Tc-99m HMPAO-labeled leukocytes. (a) Anterior view. (b) Posterior view. 5 = spleen. L = liver. (2) Normal activity in the kidneys. (a) Three hours after injection, there was prominent urinary activity (arrows) in both collecting systems and minimal renal parenchymal activity in this thin male patient with a negative image. ease. (b) Prominent renal parenchymal activity (arrow) but no collecting system activity in a patient with a negative image.

	Ith Tc-99m-labeled Leukocytes Results* Confirmation of Diagnosis								" No JH
Initial Diagnosis	TP	FP	TN	EN Disgno		Patholo	and the second	Clinical	Diagnosta
nflammatory bowel disease (n = 32)	25	O	7	0		30	ar install 1	0 .	0,
Feveral unknown origin (# # 17)	4	0	12	0	The states 2 1	12112	1. 1. 2. 20		11.1
Intraabdominal abscess (n = 21)	15	2	3	0	1.01.0	16. 161	Stand .	249 62	100
Osteomyelitis (n = 20)	4	1	- 14	0	"	1. 1 A 1 1 1 1	Part of the		1. 0.
Bronchiectasia (n = 7)	6	0	1	0 0	i i nu Di		144 4.00	6 18 1 1	
Myocardial infarction (n = 3)	0	0	0	0 7	0		17	13	6
Total (n = 100)	34	3	37	0 6	10			and the second se	

* The sentensity was 100%, the specificity 95%. TP = true positive, FP = faise positive, TN = true negative. FN = faise negative.

The reconstitution of a vial of Ceretec with Tc-99m resulted in the formation of three Tc-99m-labeled products: lipophilic Tc-99m HMPAO, which labeled the cells; secondary Tc-99m complex: and reduced, hydrolyzed Tc-99m. The amount of primary lipophilic Tc-99m HMPAO formed was measured by means of three ascending chromatographic systems according to the manufacturers' recommended methods.

An intravenous blood sample was taken about 45 minutes after injection for the calculation of labeled granulocyte recovery. For recovery to have any useful meaning, about 40 minutes must be al-

ed for complete equilibration bean circulating and marginating granulocyte pools (14-16). The cells in 1 mL of the blood sample and those in a known small fraction of the injected cell suspension were separated on a three-step discontinuous density gradient of Percoll (Pharmacia, New Jersey) in saline, and the granulocyte-associated activity was

measured (17). Recovery was calculated as the granulocyte-associated activity present in circulating blood at 45 minutes as a percentage of the injected granulocyteassociated activity. The percentage of whole blood activity present as non-cellbound activity in plasma was also calculated in blood samples taken up to 4 hours after injection.

Patients underwent Imaging at about 1, 4, and 24 hours after injection, with a gamma camera (400A or 400T; General Electric, Milwaukee) fitted with a low-energy, general-purpose or high-resolution collimator. The three patients with myocardial infarction received Tc-99m HMPAO-labeled cells in the late afternoon and underwent imaging at the beginning of the following day, or at about 16 hours. Because of this timing, they were given higher doses, about 500 MBq (13.5 mCl).

Generally, 500,000 counts per image were obtained, and images were recorded in analog and digital form. Oblique and

pelvic outlet views were obtained when considered necessary, the latter in particular being used to clearly identify bladder activity.


We assumed, on the basis of the images, that the quantitative biodistribution of Tc-99m HMPAO-labeled leukocytes was the same as that of in-111-labeled pure granulocytes. Since quantitative data on urinary and fecal excretion of free Tc-99m HMPAO (or derivatives) are not currently available, to our knowledge, we did not calculate the radiation doses to the urinary tract and colon.

RESULTS

At the time of labeling, $84\% \pm 6\%$ (mean \pm standard deviation, n = 34) of the Tc-99m HMPAO was present, $10\% \pm 5\%$ was secondary complex, and $6\% \pm 4\%$ was reduced technetium. No free pertechnetate was found.

CONTROL NO.

89917



Figures 3, 4. (3) Gallbladder activity (arrow) at 3 hours in a patient with ulcerative colitis, as seen on (a) anterior and (b) right lateral views. Note abnormal accumulation in U.e entire colon. (4) Normal image shows colonic activity at 24 hours. Note gallbladder (arrow) and bladder activity.



Figures 5, 6. (5) Abnormal uptake in the left iliac fossa (arrow) in a patient with ulcerative colitis. Views obtained (a) 30 minutes and (b) 3 hours after injection confirm the presence of inflammatory bowel disease. b = bladder. (6) Improved resolution with Tc-99m is demonstrated in a 10-year-old boy with Crohn disease involving the terminal ileum and cecum, on an image obtained 1 hour after injection.

The labeling efficiency was slightly but significantly (P < .05) higher with method B (56% ± 13%, n = 82) than with method A (49% \pm 10%, n = 18). The distribution of cell-bound activity with method A was 78%, 15%, and 7% for the granulocytes. mononuclear leukocytes, and platelets or red blood cells, respectively; with method B, the corresponding values were 77%, 17%, and 6%.

The granulocyte recovery at 45 minutes was 40% ± 13% for method A (n * 10) and 34% ± 15% for method B (n = 16). The difference was not

significant, and the overall mean recovery was 37% ± 14% (n = 26).

Normal distribution .- During the first hour, activity was seen in the lungs, liver, spleen, and bone marrow. This distribution of activity (Fig. 1) is very similar to that seen with pure granulocytes separated and labeled in plasma with In-111 tropolonate. In addition, bladder activity was seen in all patients. The kidney and renal pelvis were also occasionally seen (66%), especially in thin patients. (Fig. 2). Gallbladder activity was seen in 4%. At 4 hours, lung ac-

tivity was minimal and bone marrow uptake was more marked. The activity in liver, spleen, kidneys, and bladder remained unchanged. The gallbladder was still rarely visualized (10%) (Fig. 3). However, faint bowel activity (in the proximal colon) was visible in five patients (5%) without evidence of inflammatory bowel disease or pulmonary sepsis. At 24 hours, the normal distribution of activity remained the same as that at 4 hours, except that activity was also seen within the colon in all patients (Fig. 4).

Inflammatory disease .- All patients with inflammatory bowel disease (ulcerative colitis, Crohn disease, or radiation-induced colitis) showed intense activity in the affected bowel during the first hour, with a further increase in activity by 4 hours (Figs. 5, 6). One patient with Whipple disease and another with Behçet syndrome, both of whom had bowel involvement, did not show intense bowel activity until 4 hours. The normal bowel excretion of Tc-99m HMPAO made the 24-hour images not helpful in this group of patients unless they also had an associated abdominal abscess without enteric communication, in which case there was a further focal increase in activity (four patients). No false-positive gut activity was seen at 1 hour. Abnormal bowel activity was therefore easily distinguishable from normal bowel activity, which probably represents

Radiology + 769

Volume 166 Number 3



Figures 7, 8. (7) Cholecystitis in a 60-year-old man, manifested by fever of unknown origin. (a) Tc-99m HMPAO image at 1 hour shows uptake in the galibladder wall (arrow) but not in the lumen. (b) Tc-99m HIDA image at 1 hour (obtained 2 days later) demonstrates a nonfilling galibladder. Ir dicating that the activity seen after Tc-99m labeling represented abnormal migration of leukocytes. (6) Intraabdominal collection complicating acute pancreatitis in a 40-year-old man. (a) Early view (at 3 hours) shows the collection in the left paracolic gutter. (b) Late view (at 24 hours) again demonstrates the collection, but bowel activity is also seen in the ascending and transverse colon. This activity could be normal or could represent enteric drainage of the abdominal collection.

early biliary excretion of Tc-99m HMPAO. Of 17 patients with fever of unknown origin, 12 showed no abnormal activity. Of the five who did, two with graft-versus-host disease following bone marrow transplantation showed intense early (1-hour) uptake in loops of the small bowel. One patient showed intense uptake

t the site of a gastrojejunal anastonosis that had broken down. Of the remaining two patients, one had activity in the wall of a distended gallbladder (Fig. 7). No activity was seen within the lumen of the gallbladder, which was shown with Tc-99m HIDA scanning to be obstructed. Acute cholecystitis was diagnosed. The fifth patient showed early (3hour) activity in loops of the small bowel, but no final diagnosis was reached and this patient was not included in the accuracy analysis.

Of the 21 patients with suspected intraabdominal sepsis (Fig. 8), 17 had positive images with uptake in the abscess by 4 hours and a further increase at 24 hours. At laparotomy, one patient was found to have a bleeding splenic artery corresponding to the abnormal focus on the images, while in another a focus of intense uptake seen anterior to the spleen could not be confirmed with CT. These two patients therefore had false-positive results.

Twelve of the 20 patients with suspected bone sepsis had prosthetic ioints or fixation plates (Fig. 9). Two of them showed abnormal activity around the prosthesis, and infection was confirmed during surgery. One patient whose right knee was swol-

"len and painful showed several areas of focal activity around both knees, and bilateral septic arthritis was ini-

Figure 9. Osteomyelitis in a patient with a femoral nail. The nail was inserted 12 months previously, after the shaft of the femur was fractured. Images obtained 2 hours after injection show two foci of migrating cells, in the midshaft at the site of the fracture (a) and at the lower end of the nail (b). Normal circulating activity is visible in the blood pool of the limbs. (c) Radiographic appearance.

tially suspected. A sulfur colloid scan, however, showed normal bone marrow, and this case was classified as a false-positive result. Seven patients with known bronchiectasis were imaged. All showed activity in areas of bronchiectatic lung at 24 hours, but the intensity was not great. Furthermore, the 4-hour images were normal in three of these patients. One patient who received labeled cells 24 hours after a large inferior myocardial infarction showed abnormal activity in the region of the infarct 24 hours after injection, but the results were negative in two patients with documented myocardial infarctions who received Tc-99m HMPAO-labeled cells 48-72 hours after infarction.

The doses received by the target

organs-spleen, liver, and bone marrow-were 21.3 mGy/100 MBg (0.79 red/mCi), 2.5 mGy/100 MBg (0.093 rad/mCi), and 2.3 mGy/100 MBg (0.085 rad/mCi), respectively. The corresponding doses for In-111-labeled granulocytes were 716 mGy / 100 MBg (26.5 rad/mCi). 86 mGy/100 MBq (3.2 rad/mCi), and 70 mGy/100 MBq (2.6 rad/mCi), respectively. The effective dose equivalents were 0.017 mSv/100 MBg (0.063 rem/mCi) and 0.57 mSv/100 MBg (2.1 rem/mCi), respectively. The imaging dose for Tc-99m HMPAO, however, is higher than that for In-111-200 MBg (5.4 mCi) versus 12 MBq (320 µCi), giving dose ratios (Tc-99m to In-111) per imaging dose of 0.5, 0.48, and 0.55 for spleen, liver, and bone macrow, respectively.

DISCUSSION

In-111 labeling of leukocytes is useful in the detection of certain inflammatory conditions (18). However, although it has a suitable half-life for abscess imaging. In-111 is expensive and gives a high radiation dose to the target organs (bone marrow and spleen). Tc-99m is more convenient to use and gives better resolution than In-111, but no Tc-99m agents have been established for leukocyte labeling. The rationale for testing Tc-99m HMPAO is that it is highly lipophilic, which is why it is used in imaging cerebral perfusion (12).

In preliminary work (13) with method A, we found that Tc-99m HMPAO labeled cells with reasonable efficiency. Like the In-111 complexes, Tc-99m HMPAO selectively labels the leukocytes, but unlike In-111 it fortuitously labels the granulocytes with significantly more stability than the mononulcear cells. Furthermore, labeling can be performed in the presence of plasma, which we have previously shown to be beneficial to the ultimate functional integrity of the granulocytes (3).

We were unable to observe any differences in activity distribution or granulocyte recovery between methods A and B, but we have adopted method B because we prefer to maintain the cells in the highest possible plasma concentration compatible with efficient labeling. Although 102 mL of blood is routinely obtained (giving a total volume with anticoagulant of 120 mL), a smaller volume can be obtained from children and patients with difficult venous access or high neutrophil counts (>20,000/ mm³ (20.0 × 10⁹/L)).

Chromatography demonstrated that, at the time of labeling, about 85% of the Tc-99m HMPAO was lipophilic. Because of the early appearance of bladder activity and absence of thyroid activity, free activity eluting from the cells is probably in the form of a hydrophilic complex. Thus, at no stage do the images resemble those seen after direct Tc-99m HMPAO injection as for brain imaging; for instance, there is no suggestion of cerebral activity.

Activity circulating in the blood remained predominately cell bound (90%), suggesting that eluted activity is rapidly cleared from blood. Because this eluted activity originates predominately from the mononuclear cells (13), and because the agent has a high degree of selectivity for leukocytes in the first place. Tc-99m HMPAO provides an essentially pure granulocyte label. A potential disadvantage of the low level of stability in lymphocytes is the possibility of a higher frequency of chromosomal aberrations resulting from a nonlethal dose. Whether this represents a significant problem remains controversial and has been the subject of much discussion (19).

Early images suggest that the labeled leukocytes are functionally optimal, as suggested by minimal sequestration in the lungs and minimal hepatic activity, criteria that we have previously shown to be related to leukocyte activation and/or damage (20). Splenic activity is intense, but this is the result of physiologic granulocyte pooling in the spleen (14). Further evidence that the granulocytes are intact is the high recovery of granulocyte-associated activity in the blood 45 minutes after injection. This recovery was 37%, very similar -to that of pure granulocytes separated on plasma-enriched, density gradient columns and labeled in plasma with In-111 tropolonate (15) and only slightly lower than the 45% reported for granulocytes labeled with phosphorus-32 diisopropyl fluorophosphonate (21).

The normal distribution of activity is similar to that seen with In-111 labeling, except that bowel activity is also present. This activity probably arises from biliary excretion, but we do not know whether it is in the form of the primary lipophilic complex, which when used for cerebral imaging does undergo gnificant hepatic uptake and ultimately appears in the bowel (22), or in the form of a secondary metabolite. As with the bladder activity, we initially thought that this normal bowel activity would make it difficult to interpret abnormal abdominal activity, but this has not been the case. Thus, in patients without inflammatory bowel disease, activity does not appear in the bowel until about 4 hours after injection, whereas activity on migrating cells is usually visible in inflamed bowel much earlier than this, sometimes as early as 15 minutes after injection. Furthermore, it is much more intense than the normal activity, and in the two patients (with Whipple disease and Behçet syndrome) in whom migrated activity was not seen until 4 hours, this intensity enabled us to make a positive diagnosis of complicating inflammatory bowel disease. Bladder activity in the collecting system is cleared

early, leaving only faint parenchymal activity, and has also not caused any diagnostic confusion. It is usually identified as bladder activity by comparison of anterior and posterior images. However, it is possible that an element of urinary stasis in the kidney or collecting system could obscure, or be misinterpreted as, sepsis, or, conversely, that migrated neutrophil activity could be misinterpreted as bladder activity.

Only four of 17 patients with fever of unknown origin had true-positive findings with Tc-99m-labeled leukocyte imaging a proportion consistent with the known low frequency of infection in this clinical setting (23). The majority of patients with suspected intraabdominal sepsis had

ositive findings, although there were false-positive results in two. In spite of the short half-life of Tc-99m, 24-hour views may still be helpful for confirming abscess by showing a further increase in activity. Late imaging is made possible by the stability of the Tc-99m in the abscess.

Osteomyelitis has always been thought of as difficult to demonstrate with labeled leukocytes, and gallium-67 has been proposed as a superior radionuclide (24). However, we have had good results with labeled leukocytes in osteomyelitis (25), and our success may be due to the use of pure granulocytes and maintenance of the cells in plasma throughout labeling. Abundant bone marrow activity is seen with these cells, probably as the result of reticuloendothelial destruction in bone marrow (16); this may interfere with the interpretation of the images in bone infections. Thus, we had false-positive results in one case in this clinical category. Imaging the bone marrow with Tc-99m sulfur colloid after leukocyte labeling is therefore often helpful. Bone marrow activity seemed more intense than after In-111 labeling of granulocytes, possibly because of the higher photon flux.

Bronchiectasis has previously been reported to appear markedly abnormal on In-111-labeled leukocyte images (26), and so our finding of only minimally positive images was somewhat disappointing and puzzling. This may partly be explained by the normal pulmonary uptake of free amine (22), which elevates the lung background activity.

In-111 labeling of leukocytes has been proposed as a means of monitoring myocardial inflammation after infarction but has not been successful (27). One explanation is the relatively poor resolution with In-111. Berause of improved resolution and

ih photon flux, Tc-99m labeling ...ay offer an exciting new approach to the study of myocardial inflammation. Of the three patients with myocardial infarction in our series, the results were positive only in the one patient who was studied within 24 hours of infarction. Although they had elevated enzyme levels and electrocardiographic changes indicative of infarction, all three patients were classified as having ho final diagnosis, since we had no alternate method to confirm granulocyte migration into the myocardium.

.

ž

i.

2

1

х.

As expected, the radiation dose is less with Tc-99m labeling than with In-111 labeling. Our calculated values for the effective dose equivalents are very similar to previously reported values for both agents (28).

In conclusion, Tc-99m HMPAO-labeled leukocytes have been successfully used for imaging a wide variety of inflammatory processes, with an accuracy comparable to that achieved with In-111 labeling. In addition to greater convenience and a reduced radiation dose, Tc-99m labeling en-

"les the imaging of low-grade in-

nmatory processes not readily imeged with In-111. We believe that Tc-99m will soon be the preferred agent for routine abscess imaging.

Acknowledgments: We are grateful to Melwyn J. Myers, Ph.D., for doing the dosimetric calculations and to Tracey Reedy for typing the manuscript.

References

 Thakur ML, Lavende, JP, Arnot RN, Slivester DJ, Segal AW, Indium-111-labeled autologous leukocytes in s. n. J Nucl Med 1977; 18:1014-1021.

 Knochel JQ, Koehler PR, Ley TG, Welch DM, Disgnosis of Caratrian all abscesses with computed tomography, ultrasound, and In-111 leukocyte scans. Radiology 1980; 137:425-432.

- Peters AM, Saverymultu SH, Reavy HJ, Danpure HJ, Osman S, Lavender JP, Imaging Inflammation with 111-indium-tropolonate labeled leukocytes. J Nucl Med 1983, 24:39-44.
- Becker W, Fischbach W, Reiners C, Borner W. Three phase white blood cell scan: diagnostic validity in abdominal inflammatory disease. J Nucl Med 1986; 27:1109-1115.
- Wistow BW, Grossman ZD, McAlee JG, Subramanian G. Henderson RW, Roskopf KML. Labeling of platelets with oxine complexes of 7c-99m and In-111. I. In vitro studies and aurvival in the rabbit. J Nucl Med 1978; 19:483-487.
- Linhart N, Bok B, Gougerot M, Gaillard MT, Melgnan M. Tc-99m labelled human leucocytes: an in vitro functional atudy. Acta Haematol 1980; 63:71-80.
 Kelbaek H, Fogh J. Technetium-99m la-
- Kelback H, Fogh J. Technetium-99m labeling of polymorphonuclear leukocytes: preparation with two different atannous agents. J Nucl Med 1985; 26:68-71.
- Zanelli GD, Bjarnason I, Smith T, Crawley JCW, Levi AJ. Copeland RI. Technetium-99m labelled porphyrin as an imaging agent for occult infections and inflamma-
- tion. Nucl Med Commun 1985; 7:17-21.
 Scroth HJ. Oberhausen E. Berberich R. Cell labelling with colloidal aubstances in whole blood. Eur J Nucl Med 1981; 6:469-
- 472.
 JU Pullman W, Hanna R, Sullivan P, Booth JA, Lomas F, Doe WF. Technetium-99m autologous phagocyte scanning: a new imaging technique for inflammatory bow-
- el disease. Br Med J 1986; 293:171-174. 11. Peters AM, Lavender JP, Danpure HJ, Osman S, Saverymuttu SH. Technetium-99m autologous phagocyte scanning. Br Med J 1986; 293:450-451.
- Ell PJ, Hocknell JML, Jarritt PH, et al. A technetium-99m labelled radiotracer for the investigation of cerebral vascular disease. Nucl Med Commun 1985, 6:437-441.
- Peters AM, Danpure HJ, Osman S, et al. Clinical experience with 99m-Tc-hexamethylproplyeneamine oxime for labelling leucocytes and imaging inflammation. Lancet 1986; 2:946-949.
- Peters AM, Saverymutru SH, Keshavarzian A, Reavy HJ, Lavender JP. Splenic pooling of granulocytes. Clin Sci 1985; 68:283-289.
- Peters AM, Savorymuttu SH, Bell RN, Lavender JP. Quantification of the distribution of the marginating granulocyte pool in man. Scand J Haematol 1985; 34:111-120.
- Saverymuttu SH, Peters AM, Keshavarzian A, Reavy HJ, Lavender JP. The kinetics of 111-indium distribution following injection of 111-indium labeled autologoua granulocytes in man. Br J Haematol 1985; 61:675-685.

- Danpure HJ, Oaman S, Hogg N, Selvendran YS, Epenetos AA. The use of three 1-125 leucocyte specific monoclonal antibodies to selectively radiolabel monocytes and granulocytes in whole blood. In: Schmidt HAE, Ell PJ, Britton KE, eds Nuklearmed 23rd Congress Soc Nuc Med Europe 1986, 363-365.
- Feters AM, Saverymuttu SH. The value of indium-labelled leukocytes in clinical practice. Blood Rev 1987; 1:65-76.
 Meignan M, Wirquin E. Lymphocyte ra-
- Meignan M, Wirguin E., Lymphocyte radiolabeling: a challenge to their survival. J Nucl Med 1987; 28:1228-1229.
- Saverymuttu SH, Peters AM, Danpure HJ, Reavy HJ, Osman S, Lavender JP. Lung transit of 111-In-labelled granulocytes: relationship to labelling techniques. Scand J Haematol 1983, 30:151-160.
- Athens JW, Mauer AM, Ashenbrucker H, Cartwright GE, Wintrobe MM. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. J Clin Invest 1961; 40:150-164.
- Costa DC, Ell PJ, Cullum 1D, Jarritt PH. The in-vivo distribution of technetium-99m-HMPAO in normal man. Nucl Med Commun 1986; 7:647-658.
- Larson EB, Featherstone HJ, Petersdorf RG. Fever of undetermined origin: diagnosis and follow-up of 105 cases, 1970-1980. Medicine 1982; 61:269-292.
- Schauwecker DS, Park HM, Burt RW, et al. Evaluation of complicating esteomyelitis with Tc-99m MDP, In-111 granulocytes and Ga-67 citrate. J Nucl Med J984; 25:849-853.
- Pring DJ, Henderson RG, Rivett AG, Krausz T, Coombs RRH, Lavender JP. Autologous granulocyte scanning of painful prosthetic joints. J Bone Joint Surg [Br], 1986; 68:647-652.
- Peters AM, Needham SG, Currie DC, Cole PJ, Lavender JP. Indium-111 labelled granulocyte migration in bronchiectasia (abstr.). J Nucl Med 1986, 27:950-951.
- Davies RA, Thakur ML, Berger HJ, Wackers PJ, Gottschalk A, Zaret B. Imaging the inflammatory response to acute myocardial infarction using 111-indium labelled autologous leukocytes. Circulation 1981; 63:826-832.
- Johansson L. Mattson S. Nossiin B. Effective dose equivalents from radiopharmaceuticals. Eur J Nucl Med 1984; 9:485-489.

89917

CONTROL NO.

Technical Notes

In Vitro and In Vivo Evaluation of Granulocyte Labeling with [^{99m}Tc]d,1-HM-PAO

L. Mortelmans, S. Malbrain, J. Stuyck, C. De Backker, M. J. Heynen, M. Boogaerts, M. De Roo, and A. Verbruggen

Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Department of Medical Research, Laboratory of Hematology, K. U. Leuven, Department of Orthopaedic Surgery, University Hospital St. Pieter, Leuven, Laboratory of Radiopharmaceutical Chemistry, J. F. W., K. U. Leuven, Belgium

The functional integrity of white blood cells labeled with [^{sem}Tc]d,I-HM-PAO containing variable amounts of the ligand or of the ^{sem}Tc activity was evaluated by enzymatic tests and by measuring random migration, chemotaxis, phagocytosis, killing, and adhesion. The ultrastructure of labeled cells was studied by electron microscopy. The tracer dose and the HM-PAO concentration did not significantly affect phagocytosis and killing. The results of the other tests remained normal. A maximum labeling efficiency of 80% was reached by incubating the granulocytes for 20 min with 10–20 mCi of [^{sem}Tc]d,1-HM-PAO containing 50 µg of the ligand in 1 mi of saline. There was only a slow washout of 20% of activity from the labeled cells in 24 hr. The ultrastructure was not influenced by the labeling technique. Proven infection sites of 17 orthopedic patients were clearly visualized. After a short transient lung uptake, there was a clear spleen and moderate liver uptake with early bladder and late prominent colon visualization. Because of the lower cost, favorable radiation dose and more suitable tracer characteristics, this technique is a promising alternative for ¹¹In labeling of white blood cells.

J Nucl Med 30:2022-2028, 1989

Indium-111- (¹¹¹In) labeled white blood cells have been used for years in the detection of infection. This technique combines both high sensitivity and specificity but the nonideal physical characteristics of the radionuclide are a disadvantage. As technetium-99m (^{som}Tc) is the preferred radioisotope in view of its availability, ideal physical characteristics and low cost, many attempts have been made for more than 15 years to replace indium by technetium (1,2).

The most successful approaches to incorporate ^{90m}Tc in granulocytes have been the reduction of pertechnetate by stannous compounds diffused in the WBC in a similar way as used in red blood cell labeling (3-5) and the incorporation of ^{90m}Tc colloids by phagocytosis (6.7). In an animal study with ^{90m}Tc-labeled granulocytes obtained by the stannous pyrophosphate reduc-

tion method. Harper et al. mentioned the same radiation dose and less of a tendency to accumulate in the pus as compared to ¹¹¹In-labeled cells (3). Using WBC labeled with ^{seem}Tc colloids, Hanna and coworkers found a prolonged lung transit time that can be explained by aggregation or activation of the neutrophils (6). The results reported by Gil et al. when using stannous glucoheptonate as reducing agent could not be confirmed in our laboratory (8).

Recently, Peters et al. (9) described the possibility of labeling granulocytes with [^{oom}Tc]hexamethylpropylene amineoxime ([^{oom}Tc]-d.1-HM-PAO), a new radiopharmaceutical introduced for brain imaging (10,11). Because of its lipophilic character this agent is able to diffuse through the cell membrane and apparently binds intracellularly. The underlying mechanism is not fully understood.

The aim of the present study is the evaluation of this new labeling technique by checking the in-vitro and in vivo behavior of the technetium-labeled cells. The integrity of the cells was tested by means of electron

The Journal of Nuclear Medicine

Received Feb. 24, 1988; revision accepted July 28, 1989.

For reprints contact: L. Mortelmans, MD. Dept. of Nuclear Medicine, University Hospital Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium.

microscopy and enzymatic and functional tests. Clinical studies have been performed in orthopedic patients with proven infections to demonstrate the clinical usefulness of the labeled granulocytes.

MATERIALS AND METHODS

Separation of White Blood Cells

The separation method is schematically shown in Figure 1. Sedimentation of red blood cells for 1 hr to obtain leukocyte and platelet-rich plasma (LRP) was facilitated by the addition of 2 ml of 2% (w/v) methylcellulose to a mixture of 10 ml ACD and 50 ml whole blood. After centrifugation (150 g, 5 min) of the LRP, a second centrifugation (2500 g, 7 min) of the supernatant (platelet-rich plasma or PRP) was performed follows by filtration of the supernatant (platelet-poor plasma or PPP) through a 0.45 µm filter resulting in cell-free plasma (CFP).

The leukocyte-rich pellet was resuspended in 1 ml of Hanks' balanced salt solution (HBSS) containing 0.1% albumin, and the remaining red blood cells (RBCs) were eliminated by hypotonic lysis for 20 sec. The debris of the RBC on the surface of the pellet obtained after a subsequent centrifugation (150 g, 5 min) was eliminated by gently pipetting 1 ml of HBSS and aspirating the fluid. The remaining pellet was resuspended in 2 ml of cell-free plasma.






FIGURE 1 Schematic survey of separation procedure. Further purification was performed by discontinous gradient centrifugation of the mixed WBC pellet applied on the top of three layers of Farcoll-plasma mixtures of increasing density (65%, 60%, 50% (v/v) Percoll with a density of 1.129 g/ml). The bottom layer was washed with 4 ml of 0.9% (w/v) NaCl and centrifuged (150 g, 5 min) to obtain a WBC pellet.

Labeling Method

d.1-HM-PAO was synthesized following a published procedure (11). Five micrograms of SnCl₂-2H₂O in 2.5 µl HCl 0.05 N was added to 0.5 mg HM-PAO dissolved in 1 ml of water. Neutralization of the very small amount of HCl during labeling was not necessary as the final pH was still slightly alkaline. 120 mCi of [92mTc]-NaTeO4 dissolved in 4 ml saline was added. The preparation was diluted with saline to a concentration of 20 mCi/ml. The pellet of granulocytes after Percoll separation was resuspended immediately in 20 mCi of [^{wom}Te]d.1-HM-PAO in saline (1 ml) or was first resuspended in 1 ml of 0.9% NaCl and then added to 20 mCi of [99mTc] d.1-HM-PAO in 1 ml. The incubation time was 20 min. After centrifugation, the radioactivity associated with the cells was determined. Before use, each preparation of ["""Tc]-d.1-HMPAO was analyzed by thin-layer chromatography on ITLC SG sheets with acetone and saline as mobile phases to check for "polar" ["""Te]HM-PAO and pertechnetate, respectively. Paper chromatography with acetonitrile-water (1:1) as the mobile phase was used to determine the content of colloidal ""Te. Only preparations with a radiochemical purity over 88% were used for WBC labeling.

Evaluation of the Incorporation and the Washout of the Tracer

Aliquots of the incubation mixture were withdrawn at different time intervals (5, 10, 15, 20, 25, 30, 40, 50, and 60 min), and the radioactivity in the cells and the supernatant was measured after centrifugation.

After labeling, the cells were resuspended in plasma and preserved at 37° C for 24 hr after labeling. Aliquots were taken at 1, 2, 3, 4, 5, and 24 hr, and the radioactivity associated with the cells was measured after centrifugation.

In Vitro Tests of Granulocyte Function

1. In the first experiment (n = 3), the cells $(30 \times 10^{\circ})$ were incubated for 20 min with different concentrations of HM-PAO (0.05, 0.25, and 0.5 mg HM-PAO/mf). The added amount of tracer varied between 1 and 15 mCi.

2. In a second experiment (n = 3), the tracer dose, dissolved in a constant volume, was varied (0, 1, 5, and 15 mCi) while the concentration of HM-PAO (0.25 mg/ml), the incubation volume (1 ml), and the number of cells (40×10^6) were kept constant.

The labeled cells obtained in these experiments were evaluated with the following enzy natic and functional tests.

The inveloperoxidase (MPO) content of granulocytes was assayed spectrophotometrically using a horseradish peroxidase standard. Enzyme activity is expressed in units of MPO/2.10° PMN. Normal values: 11.28 ± 2.91 units/2 × 10° granulos cytes.

Superavide generation (SQ) was quantified spectrophotometrically at 350 nm by the superoxide dismutase-sensitive reduction of ferricytochrome C. Zymosan activated by autologous serum (SAZ, 0.5 ml/10³ PMN) was used as standard stimulant in a concentration of 2.5 ng/dl. The results are

CONTROL NO. 89912023

expressed as ninol of cytochrome C reduced per 5.10' PMN in 15 minutes. Normal values: 26.91 ± 3.31.

Chemiotaxis was evaluated by measuring the migration (am) under agarose (0.9% w/v agarose). ZAS (zymosan activated serum) and FMLP (formyl-methionyl-leucyl-phenylaline) were used as chemoattractants. Normal values random migration 430 \pm 90 µm, chemotaxis ZAS 1040 \pm 310 µm; FMLP (340 \pm 270 µm.

Phagocytosis and intracellular killing capacity of granulocytes were assayed using a pour-plating lechnique. The results are expressed as a percentage of *Staphylococcus aureus* phagocytosed and of *Staphylococcus aureus* killed after 20 min. The killing/phagocytosis index is an accurate measure of granulocyte antibacterial efficiency. Normal values are: phagocytosis: $83.03 \pm 5.07\%$: killing: $72.7 \pm 6.26\%$; killing/phagocytosis index: 0.86 ± 0.04 .

Adherence was assayed by the ability of PMN to adhere to gelatin-coated plastic surfaces (overnight coating of culture plates with 1% gelatin solution). Labeled PMN and a free chelator were added to each well and preincubated at 37^{*} C, after 10 min, the stimulant (FMLP $10^{-1}M$) was added and the plates incubated for another 30 min. The supernatant was then carefully removed, and the pellet was washed twice with warm HBSS-ALB, and then lysed twice with NaOH 0.1 N. The radioactivity in the supernatant and pellet was counted and results expressed as percent adherence. Each assay was performed in quadruplicate, and the results were calculated as the mean percentage of adherence or the mean percentage of control.

Electron Microscopy

Cell pellets were resuspended in 1.5% v/v glutaraidehyde in 0.1M cacodylate buffer (pH 7.3; 370 mOsm/l) for 30 min at room temperature. After washing in 0.1M cacodylate buffer containing 4% w/v sucrose (pH 7.3; 320 mOsm/l), the cells were postfixed for 1 hr in 1% w/v OsO4 in Sorensen phosphate buffer (pH 7.3; 350 mOsm/l). Cells were washed in cacodylate huffer containing sucrose and stored overnight in 70% v/v alcohol in water. After dehydration in a graded series of ethanol and washing in propylene oxide, the cells were resuspended in a mixture of 1 volume of propylene oxide and 4 volumes of epon for 1 hr. After centrifugation, the propyleneoxide-epon mixture was replaced by epon. The cells were embedded in Beem polyethylene capsules and centrifuged at 9,000 g for 30 min before polymerization.

The cell pellets were sectioned with a diamond knife on an LKB III microtome. Ultrathin sections, stained with aranyl acetate and lead citrate, were examined with an electron microscope (Zeiss EM 10).

Patient Studies

Seventeen orthopedic patients with proven infections were injected with leukocytes labeled with 10-17 mCi of [sumTc]d.1-HM-PAO: eight patients with an infected fracture, seven with an infected total hip prothesis, one with a malum perforans, and one with an infected joint after an intra-articular injection. All the infections were confirmed by cultures, elinical evaluation, radiology, or surgical findings. Eleven patients were injected under a double-headed camera (SELO GAMMA CAT) interfaced to a computer system (PDP 11/34 (DEC)) and were continuously monitored to evaluate lung, liver, and spleen uptake. Delayed images were made 3-4 hr and 21 hr postiblection. Two experienced readers graded the images as follows: 0: negative: 1: possibly positive: 2: suspect: 3: positive

RESULTS

The incorporation of [""Tc]d.1-HM-PAO in the white blood cells and the washout of the radionuclide in function of time is shown in Figures 2 and 3. The results of the functional tests of granulocytes labeled with varying amounts of HM-PAO are presented in Table 1. The results of the same tests obtained with a constant amount of HM-PAO but varying tracer activities are shown in Table 2.

The ultrastructure of a neutrophil granulocyte cell after labeling is shown in Figure 4.

Figure 5 shows the time activity curves during the first hour in the region of the lungs, the spleen and the liver of one of the patient studies. A clinical example of uptake of ^{sum}Tc-labeled WBC in an infected fracture of the left ankle of a patient is illustrated in Figure 6. Eleven patients had the highest score: two patients were scored as highly suspect: three were interpreted as possibly infected; and one had a negative scan.

DISCUSSION

The most important reasons for investigation of a labeling technique with ^{sym}Te are the better physical characteristics of the tracer, the lower radiation dose.




FIGURE 2

Incorporation of [^{99m}Tc]HM-PAO in the leukocytes (%) versus time for two different incubation volumes. (*) The granulocytes (60 × 10⁶) are resuspended in 1 mi of 0.9% NaCl and 1 mi [^{99m}Tc]HM-PAO (54 µg HM-PAO; 11.1 mCi of ^{99m}Tc). (*) The granulocytes (60 × 10⁶) are resuspended in 1 mi [^{99m}Tc]HM-PAO (54 µg HM-PAO; 12.7 mCi of ^{99m}Tc).




FIGURE 3

Percentage of the radioactivity retained in the cells versus time. After labeling (cfr. Figure 2; method 2), the granulocytes were resuspanded in plasma and kept at 37°C for 24 hr. Sequentially the radioactivity remaining in the cells was measured.

the lower cost, and the ready availability of a ⁴⁰Mo-^{90m}Tc generator. Peters et al. (9) recently introduced [^{90m}Tc]d,1-HM-PAO labeling of WBC as a new alternative to currently used methods of labeling with ¹¹¹In or ^{99m}Tc. Many papers have since described the use of this technique to replace ¹¹¹In labeling of granulocytes (12-22). The success and usefulness of this labeling method will greatly depend on the functional integrity

of the white blood cells after labeling, which is necessary for their localization at the inflammation site.

As illustrated by a previous study, it is essential to perform granulocyte functional tests in vitro on the purest possible cell population because contaminating cells (platelets, monocytes) definitely influence the results of the very sensitive granulocyte tests to a varying extent (23). For this reason, further steps like hypotonic lysis and percoll gradient were added to the separation procedure. Although it is well known that some activation of cells certainly occurs and although there may be some phagocytosis of silica particles present, sufficient granulocyte functional capacity is preserved to perform experiments in controlled conditions. Phagocytosis, in particular, is still sufficient, as is illustrated by its control value of 93% and 86% (Tables 1 and 2). The labeling of RBC fragments by lipid soluble tracers after the hypotonic lysis is prevented by three extra separation steps: (a) centrifugation of the isotonic mixture. (b) gently pipetting and aspiration of 1 ml of HBSS for the elimination of the debris of the RBC, and (c) further purification by discontinuous gradient centrifugation. Labeling of the isolated cells in saline was performed to enhance the labeling yield since the results of functional and morphologic tests could not demonstrate a deleterious influence of short incubation of the granulocytes in a medium without plasma.

As published previously (24), the separation technique developed in our laboratory delivers functionally and morphologically intact cells. In this study, normal values of lung transit time and spleen and liver uptake were measured, which is an argument that the leukocytes were not affected by the labeling procedure (Fig. 5).

CONTROL NO. 89917 2025

		ocytes Labeled with Different HM-PAO Concentrations HM-PAO						
"est	Blanc	0.05 mg/ml	0.25 mg/ml	0.5 mg/ml				
NIPO SICI Pracocytosis (°«) Nung (1-) K P-ncex	$\begin{array}{c} 11.9 \pm 1.3 \\ 27.1 \pm 0.7 \\ 93.3 \pm 1.8 \\ 63.6 \pm 4.9 \\ 0.90 \pm 0.04 \end{array}$	$\begin{array}{c} 11.2 \pm 2.0 \\ 26.7 \pm 1.5 \\ 84.7 \pm 9.3 \\ 69.4 \pm 14.7 \\ 0.81 \pm 0.09 \end{array}$	$\begin{array}{c} 11.9 \pm 1.8 \\ 27.1 \pm 1.7 \\ 89.2 \pm 1.7 \\ 60.6 \pm 17.4 \\ 0.68 \pm 0.19 \end{array}$	$\begin{array}{c} 11.7 \pm 1.5 \\ 26.7 \pm 2.9 \\ 83.2 \pm 10.5 \\ 61.7 \pm 22.8 \\ 0.73 \pm 0.19 \end{array}$				
Chemotaxis (µm) EMLP ZAS RM	1930 ± 352 1650 ± 260 600 ± 165	2040 ± 393 1440 ± 453 670 ± 165	2080 ± 035 1780 ± 195 660 ± 137	2060 ± 330 1720 ± 200 627 ± 139				
Adhesion Basai atyup	27.4 60.7	16.1 ± 7.5 56.4 ± 7.9	20.5 ± 8.4 50.0 ± 5.2	28.9 ± 7.2 53.7 ± 9.0				

TABLE 1

Myeccercx case content (units MPO/2 10* PMN).

* Supercix de generation (nmo) of cytochrome C reduced per 4.10° PMN in 15 min.

* Formyl memonyl leucyl phenylaline

¹ Zymosan activated serum

* Random migration.

TABLE 2

Functional and Enzymatic	Test of Leukocytes Labeled with a	Constant Amount of HM-PAO
	and increasing semitic Activities	

		mCi Phinte						
Test	Blanc	φ	1	5	16			
S.O. Chemotaxis (µm)		20.5	25.0	25.6	25.0			
FMLP ZAS RM Phagocytosis (%) Killing (%) K/F-Index Adhesion (%)	1790 ± 288 1517 ± 90 375 ± 93 86 5 ± 9.2 75.1 ± 15.6 0.86 ± 0.10	1598 1453 345 85.0 70.9 0.83	1875 1500 440 96.2 85.2 0.88	1643 ± 169 1430 ± 62 350 ± 46 86.9 ± 8.2 75.0 ± 11.0 0.86 ± 0.09	1640 ± 148 1437 ± 76 367 ± 38 89.2 ± 6 1 79.2 ± 17.4 0.85 ± 0.10			
Basal	42.6 61.2		43.0 66.0	37.8 ± 4.5 60.0 ± 5.6	38.6 ± 6.0 58.4 ± 7.8			

From the results in Tables 1 and 2, it is clear that random migration, chemotaxis (FMLP and ZAS), and adhesion of the labeled granulocytes are not influenced by labeling with different amounts of tracer and/or HM-PAO. The results in Table 1 suggest that phagocytosis and killing are possibly slightly affected, but there is no clear correlation with the HM-PAO concentration. To exclude the potential influence of the amount of radioactivity, the same tests were repeated after labeling with a constant amount of HM-PAO but with increasing activities of ^{sym}Tc. The normal results of these tests indicate that the results of the first experiments were probably within the limits of experimental error. Normal in vitro results have also been reported by other authors (12, 15, 18).

Figure 2 shows that during the labeling step an equilibrium is reached 20 min after resuspending the white blood cell pellet in 1 ml of the [^{99m}Tc]d,1-HM-PAO solution. Resuspension of the white blood cells in 1 ml of physiologic saline before addition of the ^{99m}Tc complex results in a slower and less efficient tracer uptake, probably due to the dilution effect. The mean separation efficiency expressed as a percentage of the number of leukocytes present in the patients' blood was 40%




FIGURE 5


Time-activity curves in the region of the lungs, spleen, and liver during the first hour after injection of 15 mCi of autologous ^{sym}Tc-labeled granulocytes.



FIGURE 4

Electron micrograph of a ^{sem}Tc-labeled neutrophil granulocyte. The cell profile has a slightly irregular outline. Azurophil (A) and neutrophil (N) granules, mitochondria (M), and polyribosomes (arrow) are dispersed in the cytoplasm. Three nuclear profiles (*) are visible. The Goigi apparatus (G) is localized in the nuclear region. The shape, organization, and ultrastructure of the labeled cells do not appear to differ from that of the control cells (× 20,000).

The Journal of Nuclear Medicine



4 hr p.i.

FIGURE 6

WBC scan is shown of a patient with a left bimalleolar ankie fracture. He was treated 6 mo ago with an open reduction and was admitted to the hospital with complaints of pain and inflammation. On the upper ray: the anterior projection of both ankies and the left lateral and medial projection of the left ankie 1 hr postinjection are shown. There is a clear uptake of labeled cells in the distal tibia and the left ankie. The same projections 3 hr postinjection are shown on the lower ray. A more focal accumulation in the medial malleolus, distal tibia and ankle joint is shown. The three-phase skeletal scintigraphy was positive in all phases. The x-rays of the left ankle were compatible with a septic arthritis. The cultures of the exudate showed the presence of *Staphylococus aureus*.

(range 18–78). This means that, with an average leukocyte count of 7000 cells per μ l, 8 to 26 × 10° cells were used for labeling. The average labeling efficiency in the case of the 17 patients was 69.3% (range 50–81), thus demonstrating the effectiveness of our labeling method as compared to the lower results of other authors (19). As shown in Figure 3 the labeling is quite stable, and only 20% of the bound tracer activity is eluted from the cells during the first 24 hr. It is not known in which chemical form ""To is released from the cells, but free pertechnetate is excluded because no thyroid uptake has been demonstrated.

Some authors (9.79) have reported that in vitro the activity elutes less from granulocytes (6.1% over 2 hr) than from mononuclear cells (30% over 2 hr). Based on these observations, one may conclude that the white blood cell suspension obtained after the hemolysis step (Fig. 1) does not have to be purified any further by supplementary steps (gradient centrifugation, etc.). As only one-fifth of the [""Tc]d.1-HM-PAO preparation is used during the labeling step, the granulocytes were

incubated with no more than 0.1 mg of HM-PAO and 1 μ g of SnCl₂·2H₂O. The addition of such small amounts of these substances undoubtedly reduces the risk of alteration in the cell structure (Fig. 4).

Transmission electron microscopy (TEM) is a valuable tool in the evaluation of labeled cells, as was demonstrated in our previous study on the ¹¹In labeling of white blood cells with three different chelators (25). In this article, the deleterious effect of oxine and Merc on the morphology of cells was clearly demonstrated by TEM. As shown in Figure 4, the TEM image of the technetium-labeled white blood cells was completely normal, which is another argument in favor of this method.

The scintigraphic images of the patient studies have some special features. The biadder is visualized early whereas the thyroid gland was never seen. Bone marrow uptake is prominent, and there is some bowel visualization without previous hepatic secretion after 4 to 6 hr. In case of bowel disease, the early timing of the images and the intensity of the tracer uptake can be helpful in the final diagnosis (9,17). A 24-hr study with regular acquisition of the abdomen of normal persons could provide more information of the normal sequence of the intesting uptake.

The scintigraphic score was 2 (suspect) or 3 (positive) in 13 of the 17 patients. These lesions were already clearly visible at 3 hr and no extra lesion was found at 24 hr (Fig. 6). Some authors mention that most lesions become positive already 30-60 min after injection (9,10,13-15). This finding is also demonstrated in the clinical example showing a clear hot zone in the distal tibla. A more localized uptake is found on the images 3 hr p.i. There was one false-negative result with a patient with an infected fracture of the tibla. The lung transit of this study was prolonged, so this negative result could be explained by an improper separation or labeling step.

The images are as good or better than those obtained with indium-labeled WBC. This is in agreement with the findings of other authors who already used HM-PAO labeling (26,27). Comparing the images of simultaneously injected [^{aum}Tc]d,1-HM-PAO and [¹¹³In]oxinate labeled white cells in 12 patients. Lui found complete agreement in lesion detectability but a superior quality (better spatial and contrast resolution) when using the ^{aum}Tc-labeled agent (75). An additional important advantage of the ^{aum}Tc-labeled granulocytes is the lower radiation dose (9), which permits the use of higher activities.

It is concluded that labeling of leukocytes with ["""Teld.1-HM-PAO results in functionally and morphologically intact cells. The cost, availability, and physical characteristics of the tracer and the final clinical results justify this cell-labeling technique as a valuable alternative for ¹¹In labeling.

CONTROL NO.

89917

ACKNOWLEDGMENTS

The authors thank M. J. Vangoetsenhoven for her skillful secretarial work and W. Scheers for performing all of the functional tests.

REFERENCES

- Andersen BR, English D, Akalin HE, et al. Inflammatory lesions localized with technetium Tc-99m labeled leucocytes. Arch Intern Med 1975, 135:1067-1073.
- Kelbaeck H. Fogh J. Technetium-99m labelling of polymorphonuclear leucocytes: preparation with two different stannous agents. J Nucl Med 1985; 26:68-71.
- Harper RA, Menashi S, McCollum CN. In vivo cell labelling for the detection of occult sepsis. Nuklearmedizin Suppl 1987; 23:506-508.
- Kelbaeck H, Fogh J, Elmgreen J. In vitro labelling of human polymorphonuclear leucocytes with 99m-Tc. Eur J Nucl Med 1984, 9:366-369.
- Gillespie GY. Barth RF. Gobaty A. Labeling of mammalian nucleated cells with 99m-Tc. J Nucl Med 1973; 14:706-708.
- Hanna R. Braun T. Levendel A. et al. Radiochemistry and biostability of autologous leucocytes labelled with 99m-Tc-stannous colloid in whole blood. *Eur J Nucl* Med 1984; 9:216-219.
- Marcus CS, Butler JA, Henneman PL, et al. Tc-99m albumin colloid leucocyte preparation and imaging (Abstract). Nucl Med 1987; 256:241.
- Gil MC, Straub RF, Srivastara SC, et al. A new kit method for efficient labelling of leucocytes and platelets with Tc-99m [Abstract]. J Nucl Med 1986; 26:946.
- Peters AM, Danpure HG, Osman S, et al. Clinical experience with 99m-Tc-hexamethylpropylene-amineoxime for labelling leucocytes and imaging inflammation. *Lancet* 1986; 25:946–949.
- Ell PJ, Jarrit Ph, Cullum 1. et al. Regional cerebral blood flow mapping with 99mTc-labelled compound. Lancet 1985; 11:50-51.
- Neirinekx RD, Canning LR, Piper IM, et al. Technetium-99m d.1-HmPAO a new radiopharmaceutical for SPECT imaging of regional cerebral perfusion. J Nucl Med 1987; 28:191-202.
 Salehi N, Andrews JT, Technetium-99m Hexame-
- Salehi N, Andrews JT, Technetium-99m Hexamethylpropylone-amineoxime (HmPAO) labelled human platelets. A white cells optimal method [Abstract]. Nucl Med 1987; 256:198.
- Leikas S, Lantto T, Vorne M. Clinical imaging with Tc-99m-HMPAO leucocytes. Comparison with Ga-67 citrate and Tc-99m-nanocolloid [Abstract]. Nucl Med

1987: 256:90.

- Lavender JP, Feeters AM, Rodde ME, Preliminary clinical experience with Tc-99m Hm-PAO for labelling leucocytes and imaging inflammation [Abstract]. *Nucl Med* 1987: 256:90
 Lui D, Costa DC, Jarritt PH, et al. Simultaneous, dual
- Lui D. Costa DC, Jarritt PH, et al. Simultaneous, dual radionuclide labelled, white cells: In-111-oxine vs. Tc. 99m-HMPAO, A comparative study [Abstract]. Nucl Med 1987: 256:91.
- Messian O. Petiet A. Colas-Linhart N. In vitro quantification of 99m technetium labelled leukocytes migration. Comparison of several methods [Abstract]. *Nucl Med* 1987; 256:91.
 Schuemichen C. Schoelmerich J. Specificity of Te-
- Schuemichen C, Schoelmerich J. Specificity of Te-99m HM-PAO labelled leucocyte untake in the large bowel as an indicator of inflammatory bowel disease [Abstract]. Nucl Med 1987; 256:66.
- Rao SA, Aksut G, Trembath LA, et al. Evaluation of Te-99m HMPAO for leukocyte labelling [Abstract]. J Nucl Med 1987; 28:638.
- Danpure S, Osman MJ, Carroll ME, et al. In vitro studies to develop a clinical protocol for radiolabelling mixed leucocytes with Tc-99m HMPAO [Abstract]. J Nucl Med 1987; 28:694.
- Roddie ME, Peters AM, Henderson BL, et al. Imaging inflammation with Tc-99m HMPAO labelled white cells [Abstract]. J. Nucl. Med 1987; 28:648.
- Uno K. Imazeki K. Yoshikawa K. et al. Clinical use of technetium-99m HMPAO labeled leukocytes for inflammatory imaging [Abstract]. J Nucl Med 1987; 28:648.
- Mortelmans L, Verbruggen A, Boogaerts M, et al. In viero evaluation of granulocyte labelling with Te-99m HMPAO and Te-99m stannous glucoheptonate (GHA) [Abstract]. J Nucl Med 1987; 28:690.
- Boogaerts M, Vercelotti G, Roelant C, et al. Platelets augment granulocytes aggregation and cytotoxicity: uncovering of their effects of improved cell separation techniques. Scand J Haem 1986: 37:229-236.
- Mortelmans L, Verbruggen A, Malbrain S, et al. Isolation of granulocytes. Nucl Compact 1988; 19:141-145.
- Mortelmans L, Verbruggen A, Malbrain S, et al. Evaluation of In-111 labelled white blood cells by in vitro functional tests and electron microscopy. Comparison of three labelling methods. Eur J Nucl Med 1988: 14:159-164.
- Roddie ME, Peter AM, Danpure MJ et al. Inflammation: imaging with Tc-99m HMPA-labeled leukocytes. Radiology 1988; 166:767-772.
- Peters AM, Roddie ME, Danpure HJ, Tc-99m HMPAO labelled leukocytes: comparison with In-111 tropolonate labelled grenulocytes. Nucl Med Commun 1988; 9:449–463.

Technetium-99m HM-PAO-Labeled Leukocytes in Detection of Inflammatory Lesions: Comparison with Gallium-67 Citrate

Martti Vorne, Irma Soini, Tuomo Lantto, and Seija Paakkinen

Department of Nuclear Medicine, Paijat-Hame Central Hospital, Lahti, Finland, Department of Nuclear Medicine, Turku University Central Hospital, Turku, Finland

J Nucl Med 30:1332-1336, 1989

Jallium-67 (*'Ga) citrate was first shown to accumulate in inflammatory lesions in 1971 (1) and thereafter it has been used routinely in the detection of inflammation. In 1976 McAfee and Thakur (2) first investigated the use of indium-111 ("In) oxine for the labeling of leukocytes and since then ¹¹¹In leukocyte scans have been shown to be useful in detection of infections and inflammatory lesions and successfully applied to the evaluation of a variety of pathologic inflammatory conditions (3.4). The sensitivity of [67Ga] citrate and ¹¹¹In leukocytes to detect inflammation is relatively equivalent but increased specificity of ¹¹¹In leukocytes has made it the procedure of choice (4). However, [67Ga]citrate has a greater sensitivity in the identification of prolonged infections of more than 2 wk duration (5). Technetium-99m (99mTc) hexamethvlpropyleneamine oxime (HM-PAO) has recently been shown to radiolabel leukocytes in vitro (6) and promising results of its clinical use in the identification of inflammatory lesions have been published (7-11). Technetium-99m HM-PAO leukocyte method has many advantages over [11]n]oxine with respect to image quality, acquisition time, and radiation dose to the

patient and it has a promising future as an imaging agent in inflammatory diseases (9, 10, 12, 13).

In the present study we have compared [99mTc]HM-PAO leukocyte and [67Ga]citrate scan findings in a series of 43 patients suspected of having various benign inflammatory conditions.

MATERIALS AND METHODS

Patients

Forty-three patients (27 mez, 16 women, age range 25-78 yr, mean age 61 yr) were imaged with [^{sym}Tc]HM-PAOlabeled leukocytes and [⁶⁷Ga]citrate within 10 days (mean 4 days). The first study was ^{sym}Tc leukocyte scan in 40 cases and ⁶⁷Ga scan with three patients.

Seventeen patients had suspected bone or joint infection, 11 had suspected prosthetic vascular graft infection, four had suspected inflammatory bowel disease, five had suspected intra-abdominal abscess, five had fever of unknown origin, and one had suspected pulmonary infection. The final diagnosis was confirmed in every case by one or more of the following diagnostic procedures: bacteriologic culture, laboratory tests, histology, standard x-ray procedures, computed tomography, ultrasonography, endoscopy, and bone scan, in combination with clinically relevant signs and favorable response to antimicrobic therapy.

Leukocyte Labeling with [99mTc]HM-PAO

Mixed leukocytes were isolated and labeled as described previously (11). Forty milliliters venous blood was drawn into

The Journal of Nuclear Medicine

Received May 2, 1988; revision accepted Apr. 20, 1989.

For reprints contact: Martti Vorne, MD, Dept. of Nuclear Medicine, Paijat-Hame Central Hospital, SF-15850 Lahti, Finland.

	Perto leukocytes				(^{er} Ge)citrate			
Initial diagnosis	TP	FP	TN	FN	TP	FP	TN	FN
Bone or joint disease (n = 17)	8	Ó.	7	2	9	2	5	1
Prosthetic vascular graft infection (n = 11)	8	0	3	0	8	1	5	0
Inflammatory bowel disease (n = 4)	2	0	2	0	2	1	1	0
Intra-abdominal abscess (n = 5)	3	0	2	0	3	2	0	0
Fever of unknown origin (n = 5)	0	0	5	0	0	1	4	0
Pulmonary infection $(n = 1)$	1	0	0	0	1	0	0	0
Total (n = 43)	22	0	19	2	23	7	12	1

TABLE 1 Results of Imaging with ^{99m}Tc-Labeled Leukocytes and [⁶⁷Ga]Citrate

a 60-ml plastic syringe containing 10 ml acid citrate dextrose and 10 ml 6% hydroxy ethyl starch to fasten the sedimentation. The erythrocytes were allowed to sediment at room temperature for 1 hr. The supernatant was centrifuged in sterile tubes at 100 g for 5 min. The platelet-rich supernatant was separated and centrifuged at 2,000 g for 5 min to obtain cell free-plasma. Leukocytes were suspended into 1 ml cellfree plasma. Technetium-99m HM-PAO was formed by adding 600 MBq ^{99m}Tc in 6 ml isotonic saline to a vial containing HM-PAO (Ceretec, Amersham International). Five milliliter (500 MBq) of [^{99m}Tc]HM-PAO-complex was added to the leukocyte suspension which was left for 10 min at room temperature. The cells were repelletted at 100 g for 5 min, resuspended in 5 ml cell-free plasma, and reinjected intravenously. The cell labeling efficiency was 39% (range 18–72%).

Scintigraphy and Analysis of Scintigrams

Planar images were obtained at 0.5 hr, 2 hr, 4-6 hr, and 18-24 hr after the injection of 99mTc leukocytes, and 24-72 hr after the administration of 110-185 MBq of [6'Ga]citrate. Two nuclear physicians interpreted the images without the knowledge of clinical diagnosis. The intensity of uptake was graded as weak, moderate, or strong by subjective evaluation. On rare occasions when the readings differed, the final result was obtained by consensus. A scintigram was considered "true positive" when the pathologic uptake was caused by a benign inflammatory or infectious disease confirmed by other diagnostic procedures mentioned earlier. A positive scintigram was considered "false positive" when the finding was verified to be noninfectious and noninflammatory by other diagnostic modalities. A negative scintigram was considered "true negative" when no focal infectious or inflammatory benign process was found, and "false negative" when a focal infectious or inflammatory process was found by other diagnostic procedures.

RESULTS

The results of the scintigraphic examinations are presented in Tables 1 and 2. The sensitivity of [⁶³Ga] citrate was a little better than that of ^{99m}Tc leukocytes but ^{99m}Tc leukocyte scan showed much greater specificity, accuracy, and positive predictive value.

The normal distribution of the activity in ^{99m}Tc leukocyte scan was similar to that seen with ⁽¹⁾In-labeling with exception of urinary bladder visualization in all patients. The normal distribution has been described in detail previously (6.8, 9, 12-14).


All patients with true positive findings in inflammatory or infectious disease, showed abnormal uptake even at 0.5 hr after injection of 99m Tc leukocytes and the intensity of uptake increased in later images. The final diagnoses of the 17 patients with suspected bone or joint infection were four acute, two subacute, and three chronic osteitis or prosthetic joint infection; two metastatic malignancies, one reactive arthritis, and five with no inflammatory or malignant bone disease. Eight were true positive with 99mTc leukocytes and nine with [67Ga]citrate. Results in acute and subacute infections were comparable. Two patients with bone metastases, one from lung carcinoma and the other from malignant melanoma had true-negative 99mTc leukocyte scans but false-positive [67Ga]citrate scans. Two patients with chronic osteomyelitis showed false-negative i c leukocyte scans but positive [67Ga]citrate scans, however, one patient with chronic osteomyelitis was negative with [6 Ga]citrate but positive with 99m Te leukocytes. One patient with bacteriologically verified subacute prosthetic hip joint infection was moderately positive with ""Te leukocytes but only weakly positive with ⁶⁷Ga citrate (Fig. 1).

All prosthetic vascular graft infections were positive with both agents and the information obtained was relatively comparable (Fig. 2). In addition there was

TABLE 2

Sensitivity, Specificity, Accuracy, and Predictive Values of ^{sen}To Leukocyte and [^{s7}Ga]Citrate Scintigraphies in the Detection of Benign Infectious or Inflammatory Diseases

	secto leukocyte	(6'Ga)citrate
en en de la caracita de la caracita La caracita de la cara	CONTRACTOR OF A DESCRIPTION OF A DESCRIP	A C
Sensitivity (%)	92	96
Specificity (%)	100	63
Accuracy (%)	95	81
Positive predictive value (%)	100	77
Negative predictive value (%)	90	92



B 99m Tc-WBC 2h 67Ga

FIGURE 1

Intected prosthetic hip joint shows marked abnormal activity in bone scan (A) and "ImiTo leukocyte scan (B) and weak

3 h

tive with ""Te leakocytes than with ["Galeitrate. The kin's disease were weakly false positive with ["Ga] known origin, which showed uptake of ["Giajcitrate but

DISCUSSION




FIGURE 2

with """To leukocytes (B).





FIGURE 3

Abdominal abscess with multiple cavities is visualized with ""To leukocytes at 0.5 hr after injection (A), the uptake is increased at 4 hr and the abscess is sharply demeated from the background activity (B). The quality of the (* Galoitrate image at 72 hr is much poorer (C).

ated with """ To leukocytes. The difference in the image quality between these two agents was most constituous in the abdominal region. Weak to moderate activity in the put was diways seen in the ["Galettrate scan in spite of bower cleansing before imaging. There was only minimal background activity in the bower up to 4–6 hr with """ To leukocytes but nonspecific bower activity was seen in some patients in the 6 hr image and large bower was always at least weakly visualized at 18–24 hr. We suggest that patients with suspected inflammation in abdominal region should be imaged during the first 4 hr after the administration of ""To leukocytes to avoid false-positive finding as was also suggested by others ("77.72").

Technetium-99m leukocstes showed no false-positive fluding whereas there were scien false-positive P'Galettrate scans. One of these panents had an old noniflaminatory and noninfected resolving pata-auttic hematoma. The other six were various mahemancles which were negative on """Te leukocyte scan. Most home metastates were seen as detects on "" Te leukocyte scan. Such a detect in skeleton is not a sponse sign of malignancy, however, because two false-negative enronic osteomyelius showed similar detects. Atthough all malignancies were true negative with "" To leakocytes and no false-positive finding has been described so far in the literature, it is probable that some malignancies will accumulate."" To leakocytes since some positive findings have been described using. "In leakocytes (73-20)

The only faise-negative finding with [* Galertrate was found in chrome osteomiventic. Gallium-67 citrate has been described to be very useful and superior to 1 In leukacytes in enrichte hone intections 14 18,21) although good results with 15 leukocytes have also been reported (27,23). Our results with 15 leukocytes were good in suspected hone or joint intection except with two of three patients having chronic disease. Note evaluations with 15 Taslabeted leukocytes are needed to make conclusions of the usefulness of this agent in chronic home intections. In acute and subacide home and joint diseases 15 Te leukocytes cave reliable intor-



A99m Tc-WBC 3h B 67Ga 42h

FIGURE 4

Anterior images of perve in a patient with metastatic lymphoma in hight lilec bone Lange detect is seen in IMTC leukocyte scan at 3 hr (A) and strong uptake in (1 Gajotrate image at 42 mr (R)

Sante.

かっていたいないのであ

mation which is in agreement with some previous studies with $^{(1)}$ In leukocytes (15.21).

Both ^{som}Te leukocytes and [67 Ga]eitrate scan were found to be very reliable in detecting prosthetic vascular graft infection, which agrees with results described previously (24-26). All five patients with fever of unknown origin were true negative with ^{som}Te-labeled leukocytes. It has been shown previously that there is very low frequency of det_vable infection in this clinical situation (27).

Recent comparisons of ^{60m}Tc leukocytes and ¹¹¹In leukocytes have shown the ^{99m}Tc method equal or better than the ¹¹¹In method and the quality of images has been better in ^{99m}Tc-labeled leukocyte scan (6.7,10,12, 13). Technetium-99m leukocytes were also superior to iodine-123-labeled monoclonal antibodies against granulocytes in a recent study (14).

In conclusion, [99mTc]HM-PAO-labeled leukocyte scintigraphy seems a very useful tool in the diagnosis of various infectious and inflammatory processes. Both the 99mTc and HM-PAO kit are readily available even for emergency use in many countries. The quality of 99mTc leukocyte image is superior to that of [67Ga]citrate and 111In leukocytes, the result is available more rapidly, and the radiation dose to the patient is lower (8,12). The usefulness of this method in chronic osteomyelitis and possibly in other chronic diseases needs further evaluation.

REFERENCES

- Lavender JP, Lowe J, Bakere JR, et al. Gallium citrate scanning in neoplastic and inflammatory lesions. Br J Radiol 1971; 44:361–366.
- McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. J Nucl Med 1976; 17:480-487.
- Segal AW, Arnot RN, Thakur ML, et al. Indium-111labeled leukocytes for localisation of abscesses. *Lancet* 1976; 2:1056–1058.
- Froelich JW. Nuclear medicine in inflammatory diseases. In: Freeman LM, Weissmann HS, eds. Nuclear medicine annual 1985, New York: Raven Press, 1985: 23-71.
- Sfakianakis GN, Al-Sheikh W, Heal A, et al. Comparisons of scintigraphy with In-111 leukocytes and Ga-67 in the diagnosis of occult sepsis. J Nucl Med 1982; 23:618-626.
- Peters AM, Danpure HJ, Osman S, et al. Clinical experience with ^{99m}Tc-hexamethylpropyleneamineoxime for labelling leucocytes and imaging inflammation. *Lancet* 1986; 2:946-949.
- Schümichen C, Schölmerich J. Tc-99m HM-PAO labelling of leukocytes for detection of inflammatory bowel disease. *NucCompact* 1986; 17:274–276.
- Paakkinen S, Vorne M, Lantto T, et al. Detection of inflammation with ^{wym}Te-HMPAO labelled leucocytes. Ann Chir Gynaecol 1987; 76:197-200.
- Roddie ME, Peters MA, Danpure HJ, et al. Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes. *Radiology* 1988; 166:767-772.
- Lui D. Costa DC, Jarritt PH, et al. Simultaneous dual radionuclide labelled white cells: In-111-oxine vs. Te-

99m-HMPAO. A comparative study. In: Schmidt HAE, Csernay L, eds. Nuklearmedizin. New trends and possibilities in nuclear medicine. Stuttgart: FK Schattuer Verlag: 1988;483-486.

- Leikas S, Lantto T, Vorne M, Clinical imaging with Tc-99m-HMPAO leucocytes. Comparison with Ga-67 citrate and Tc-99m-nonocolloid. In: Schmidt HAE, Csernay L, eds. Nuklearmedizin. New trends and possibilities in nuclear medicine. Stuttgart: FK Schattuer Verlag: 1988:477–480.
- Becker W, Schomann E, Fischbach W, et al. Comparison of ⁹⁹Tc^m-HMPAO and ¹¹¹In-oxine labeled granulocytes in man: first clinical results. *Nucl Med Commun* 1988; 9:435–447.
- Peters AM, Roddie ME, Danpure HJ, et al. ⁴⁰Te^m-HMPAO labelled leucocytes: comparison with ⁽¹⁾Intropolonate labelled granulocytes. *Nucl Med Commun* 1988; 9:449–463.
- Vorne M, Karhunen M, Lantto T, et al. Comparison of ⁽²⁾I-monoclonal granulocyte antibody and ⁹⁹Tc^m-HMPAO-labelled leucocytes in the detection of inflammation. *Nucl Med Commun* 1988; 9:623–629.
- Al-Sheik W, Sfakianakis GN, Mnaymneh W, et al. Subacute and chronic bone infections: diagnosis using In-111, Ga-67 and Te-99m MDP bone scintigraphy and radiology. *Radiology* 1985, 155:501-506.
- Becker W, Schaffer R, Borner W. Sigmoid carcinoma mimicking an intra-abdominal abscess in an ¹¹¹Inlabeled white cell scan. *Eur J Nucl Med* 1985; 11:283– 284.
- Fortner A, Datz FL, Taylor A, et al. Uptake of ¹¹¹Inleukoeytes by tumor. Am J Roentgenol 1986; 146:621– 625.
- Saverymuttu SH, Maltby P, Batman P, et al. False positive localisation of indium-111 granulocytes in colonic carcinoma. Br J Radiol 1986; 59:773–777.
- Syrjala MT, Valtonen V, Liewendahl K, et al. Diagnostic significance of indium-111 granulocyte scintigraphy in febrile patients. J Nucl Med 1987; 28:155– 160.
- Schmidt KG, Rasmussen JW, Wedebye IM, et al. Accumulation of indium-111-labeled granulocytes in malignant tumors. J Nucl Med 1988; 29:479-484.
- Schauwecker DS, Park H-M, Mock BH, et al. Evaluation of complicating osteomyelitis with Tc-99m. In-111 granulocytes, and Ga-67 citrate. J Nucl Med 1984; 25:849–853.
- McCarthy K. Velchik MG. Alavi A. et al. Indium-111-labeled white blood cells in the detection of osteomyelitis complicated by pre-existing contition. J Nucl Med 1988; 29:1015-1021.
- Pring DJ, Henderson RC, Rivett AG, et al. Autologous granulocyte scanning of painful prosthetic joints. J Bone Joint Surg (Br) 1986; 68:647-652.
- Lawrence PF, Dries DJ, Alazraki N, et al. Indium-111-labeled leucocyte scanning for detection of prosthetic vascular graft infection. J Vasc Surg 1985; 2:165-173.
- Thivolle P, Varenne L, Heyden Y, et al. Gallium-67 citrate whole body scanning for the localization of infected vascular synthetic grafts. *Clin Nucl Med* 1985; 10:330-332.
- Brunner MC, Michel, RS, Baldwin JC, et al. Prosthetic graft infections. Limitations of white blood cell scanning. J Vasc Surg 1986; 3:42–48.
- Larson EB, Featherstone HJ, Petersdorf RG. Fever of undetermined origin: diagnosis and follow-up of 105 cases, 1970-1980. *Medicine* 1982; 61:269-292.

The Journal of Nuclear Medicine

89917